 C-aryl glucoside sglt2 inhibitors
专利摘要:
The present invention provides a compound of the SGLT2 inhibitory compound of formula (I) <Formula I> (Wherein R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , lower alkyl, CF 3 , OCHF 2 , OCF 3 , SR 5i or halogen, or two of R 1 , R 2 and R 2a are bonded to Together with the carbon to form a cyclized 5-, 6- or 7-membered carbocycle or heterocycle; R 3 and R 4 are independently hydrogen, OH, OR 5a , Oaryl, OCH 2 aryl, lower alkyl, cycloalkyl, CF 3 , -OCHF 2 , -OCF 3 , halogen, -CN, -C0 2 R 5b , -CO 2 H, COR 6b , -CH (OH) R 6c , -CH (OR 5h ) R 6d , -CONR 6 R 6a , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , —SOR 5f , —S0 2 R 5 g , —SO 2 aryl, or a 5-, 6- or 7-membered heterocycle, or R 3 and R 4 are 5-membered cyclized with the carbon to which they are attached, To form a six- or seven-membered carbocycle or heterocycle; R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5 g , R 5h and R 5i are independently lower alkyl; R 6 , R 6a , R 6b , R 6c and R 6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a are 5-membered, 6 cyclized with the nitrogen to which they are attached To form a 7-membered or 7-membered heterocycle; A is 0, S, NH or (CH 2 ) n , where n is 0 to 3. The present invention also provides the SGLT2 inhibitory amount of the compound, alone or in combination with other antidiabetic or other therapeutic agents. Provided are methods for treating diabetes and related diseases for use in combination. 公开号:KR20020063876A 申请号:KR1020027004660 申请日:2000-10-02 公开日:2002-08-05 发明作者:브루스 엘스워트；윌리암 엔. 와쉬번；필립 엠. 셔；강 우；웨이 멩 申请人:브리스톨-마이어스스퀴브컴파니； IPC主号:
专利说明:
C-Aryl Glucoside SGLT2 Inhibitors {C-Aryl Glucoside SGLT2 Inhibitors} [2] About 100 million of the world's population suffers from type II diabetes (NIDDM), which is characterized by hyperglycemia due to hepatic glucose overproduction and peripheral insulin resistance, the cause of which is still unknown. Hyperglycemia is considered a major risk factor for the development of diabetic complications, and seems to contribute directly to the impairment of insulin secretion seen in advanced NIDDM. Normalization of plasma glucose in NIDDM patients is expected to enhance insulin action and offset the development of diabetic complications. Sodium dependent glucose transporter SGLT2 inhibitors present in the kidney are expected to help normalize plasma glucose levels and possibly body weight by enhancing glucose excretion. [3] There is also a need to develop new and safe oral active antidiabetic agents to supplement existing therapeutics, including sulfonylureas, thiazolidinediones, metformin and insulin, and to avoid potential side effects associated with the use of other agents. [4] Hyperglycemia is a recognized symptom of type II diabetes (NIDDM), and consistent control of plasma glucose levels in diabetes can offset the development of beta cell breakdown and diabetes complications in advanced disease. Plasma glucose is generally filtered in the glomeruli of the kidney and actively resorbed in the proximal tubules. SGLT2 is believed to be the major transporter responsible for the resorption of glucose at this location. Florinazine, an SGLT specific inhibitor, or a closely related homologue, normalizes plasma glucose levels by inhibiting the reuptake process in rodents and dogs with diabetes, thereby promoting glucose excretion without side effects of hyperglycemia. Long-term (6 months) treatment with SGLT2 inhibitors in rats with Zucker Diabetes enhances insulin response to blood glucose, enhances insulin sensitivity, and improves insulin sensitivity in these animals without the discovery of renal disease and imbalance of electrolytes in plasma. It has been reported to delay the development of nephropathy and neuropathy. Selective inhibition of SGLT2 in diabetic patients is expected to promote insulin sensitivity and delay the development of diabetic complications by enhancing the urinary excretion of glucose to normalize plasma glucose. [5] 90% of renal glucose resorption occurs in epithelial cells of the initial S1 fragment of the neocortical proximal tubules, and SGLT2 seems to be the major transporter responsible for this resorption. SGLT2 in the early S1 fragment of the renal proximal tubules 672 amino acid protein containing 14 membrane-spanning fragments that are predominantly expressed. Substrate specificity, sodium dependence and SGLT2 localization are consistent with the properties of high dose, low affinity, sodium dependent glucose transporters characterized by human renal cortical renal proximal tubules. In addition, since all sodium dependent glucose transporter activity encoded in mRNA from the rat kidney cortex is substantially inhibited by antisense oligonucleotides specific for rat SGLT2, hybrid depletion studies are performed by proximal tubules. It is associated with SGLT2 as the Na + / glucose cotransporter predominant in the S1 fragment. SGLT2 is a candidate gene for some forms of genetically abnormal, familial diabetes, in which renal glucose reuptake is impaired to varying degrees. To date, no SGLT2 positions on chromosome 16 of these syndromes have been investigated. However, studies of highly homologous rodent SGLT strongly implicate SGLT2 as the major renal sodium dependent transporter of glucose and suggest that SGLT2 modulators are encoded at mapped diabetes sites. SGLT2 inhibition is expected to reduce plasma glucose levels through enhanced glucose excretion in diabetic patients. [6] Another Na dependent glucose cotransporter, SGLT1 (amino acid concentration 60% consistent with SGLT2), is expressed in the more terminal S3 fragment of the small intestine and renal proximal tubules. Despite sequence similarity, human SGLT1 and SGLT2 can be distinguished biochemically. For SGLT1 the molar ratio of Na + to transported glucose is 2: 1, whereas for SGLT2 the molar ratio is 1: 1. Km for Na + is 32 mM and 250-300 mM for SGLT1 and SGLT2, respectively. Km values for uptake of glucose and non metabolic glucose homologues α-methyl-D-glucopyranoside (AMG) are similar to SGLT1 and SGLT2 (ie 0.8 and 1.6 mM for SGLT1 and SGLT2 transporters, respectively) (Glucose), and 0.4 and 1.6 mM (AMG). However, the two transporters change substrate specificity for sugars such as galactose, which is only a substrate for SGLT1. [7] Administration of floridine, a specific inhibitor of SGLT activity, promotes glucose release, reduces fasting and postprandial plasma glucose, and improves glucose utilization in vivo in some rodent models with diabetes and one canine diabetic model without hyperglycemic side effects. Demonstrate a facilitating concept. No adverse effects on plasma ion balance, renal function or renal morphology were observed from the results of floridine treatment for two weeks. In addition, administration of floridine to normal animals did not result in hyperglycemia or other adverse effects in the presence of diabetes. Administration of renal SGLT inhibitors for 6 months has been reported to enhance fasting and postprandial plasma glucose, insulin excretion and utilization in obese NIDDM rat models and offset the development of nephropathy and neuropathy without hyperglycemia or kidney side effects (Tanabe Seiyaku). ). [8] Since floridine is a nonspecific SGLT1 / SGLT2 inhibitor that is hydrolyzed in the digestive tract with its aglycone floretin (which is a potent inhibitor of glucose's easy transport), floridine itself is not of interest as an oral drug. Ease of co-inhibition of glucose transporter (GLUT) is undesirable because such inhibitors are predicted to exacerbate peripheral insulin resistance and promote hyperglycemia in the CNS. In addition, inhibition of SGLT1 has serious adverse consequences, as described by hereditary syndrome glucose / galactose malabsorption (GGM), where mutations in the SGLT1 cotransporter degrade glucose uptake in the gut and cause fatal diarrhea and dehydration. Can be. Biochemical differences between SGLT2 and SGLT1, as well as the degree of sequence difference between them, allow for the identification of selective SGLT2 inhibitors. [9] Familial diabetes syndrome is a condition in which the intestinal glucose transport and the renal transport of other ions and amino acids are normal. Familial diabetics appear to develop normally, have normal plasma glucose levels, and have no major health deficiencies as a result of this disease, even if the level of glucose released is sometimes very high (110-114 g / day). . For these patients, evidence of major syndromes includes polypagia, polyuria and polydiffsia, and the structure and function of the kidneys appears to be normal. Thus, from the available evidence so far, kidney reuptake defects in glucose appear to have minimal long-term negative consequences in other normal individuals. [10] The following references disclose O-aryl glucoside SGLT2 inhibitors for the treatment of diabetes. [11] EP 598359A1 (also JP 035988) (Tanabe Seiyaku) discloses compounds of formula (A). [12] [13] Wherein R 1 is H or acyl, R 2 is H or Me, and R 4 may be various substituents [14] EP 0850948 A1 discloses compounds of formula (B). [15] [16] Wherein R 1 is H, acyl or CO (Oalkyl), R 2 is H or allyl and R 3 is H or Me [17] JP 09188625A has the structure of Formula B, wherein R 3 is H, and the 5-membered ring contains examples of saturated Formula B, as well as corresponding portions of benzothiophene (0 = S) and indene (0 = CH 2 ). I will add. [18] [19] Wherein R 1 is H, acyl or CO (Oalkyl), R 2 is H or allyl and R 3 is H or Me [20] JP 09124685A further expands the following Formula B (R 3 = H) comprising a derivative of mono acylated C6 hydroxyl, wherein the acyl group is saturated benzoic acid or pyridyl carboxylic acid or a urethane prepared from the corresponding phenol. . [21] [22] (Wherein R 1 is H, acylaryl or CO (Oaryl) and R 2 is H) [23] JP 09124684 discloses a derivative of formula (B) below. [24] [25] Wherein R 1 and R 2 are each H, alkyl, alkoxy or aryl, or together form oxo [26] EP 773226-A1 discloses derivatives of formula B below. [27] [28] (In the case of R 2 is H R 1 is the case of alkanol and, R 1 is H R 2 is alkoxycarbonyl) [29] JP 0080006-A discloses derivatives of formula A in which various combinations of glucose hydroxyls are acylated and appear similar to EP 598359A1. [30] EP 684254-A1 appears to comprise derivatives of formula B disclosed in JP 09188625A. [31] Other publications and publications that disclose SGLT2 inhibitors include the following: [32] K. Tsujihara et al., Chem. Pharm. Bull. 44, 1174-1180 (1996) [33] M. Hongu et al., Chem. Pharm. Bull. 46, 22-33 (1998) [34] M. Hongu et al., Chem. Pharm. Bull. 46, 1545-1555 (1998) [35] A. Oku et al., Diabetes, 48, 1794-1800 (1999) [36] JP 10245391 (Dainippon) discloses compounds having 500 structures as hyperglycemic agents for treating diabetes. These are the 0-glucosides of hydroxylated coumarins. [37] WO 98/31697 discloses compounds having the structure: [38] [39] Wherein Ar is in particular phenyl, biphenyl, diphenylmethane, diphenylethane and diphenylether, R 1 is glycoside and R 2 is H, OH, amino, halogen, carboxy, alkyl, cyclo Alkyl or carboxamido, R 3 is hydrogen, alkyl or acyl, and k, m and n are independently 1 to 4) A subset of the compounds disclosed in WO 98/31697 is in particular an inflammation Compounds of the formulas disclosed below for use in the treatment or prevention of diseases, autoimmune diseases, infections, cancer and cancer metastases, reperfusion diseases, thrombosis, ulcers, wounds, osteoporosis, diabetes mellitus and atherosclerosis. [40] [41] Wherein A is O or (CH 2 ) X (where x is 0 to 3), R 3 is hydrogen, alkyl or acyl group where n is 1 to 4, and R 2 is hydrogen , Alkyl, OH, NH 2 , halogen, CO 2 H or carboximide, where k is 1 to 4 [1] The present invention relates to C-aryl glucoside, which is an inhibitor of sodium dependent glucose transporter (SGLT2) found in the intestine and kidney, and to such C-aryl glucoside, alone or in one, two or more other types of Diabetes, in particular type II diabetes, as well as hyperglycemia, hyperglycemia, obesity, hypertriglycerides, used in combination with one, two or more other types of therapeutic agents, such as antidiabetics and / or hyperlipidemia The present invention relates to a method for treating hypertension, syndrome X, diabetes complications, atherosclerosis and related diseases. [42] According to the present invention there is provided a C-aryl glucoside compound having the structure of formula (I), and pharmaceutically acceptable salts, all stereoisomers and prodrug esters thereof. [43] [44] Where [45] R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , alkyl, CF 3 , OCHF 2 , OCF 3 , SR 5i or halogen, or two of R 1 , R 2 and R 2a to which they are attached A cyclized ring to form a 5-, 6- or 7-membered carbocyclic ring with carbon, or contain 1 to 4 N, 0, S, SO and / or SO 2 heteroatoms in the ring; Can form a 5-, 6- or 7-membered heterocycle; [46] R 3 and R 4 are independently hydrogen, OH, OR 5a , Oaryl, OCH 2 aryl, alkyl, cycloalkyl, CF 3 , -OCHF 2 , -OCF 3 , halogen, -CN, -C0 2 R 5b ,- CO 2 H, COR 6b , -CH (OH) R 6c , -CH (OR 5h ) R 6d , -CONR 6 R 6a , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -S0 2 R 5 g , -SO 2 aryl, or a 5 or 6 membered group which may contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring Or a 7-membered heterocycle, or R 3 and R 4 together with the carbon to which they are attached form a 5-, 6- or 7-membered carbocyclic ring, or 1 to 4 N, 0, S, SO in the ring And / or form a cyclized 5-, 6- or 7-membered heterocycle which may contain a SO 2 heteroatom; [47] R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5 g , R 5h and R 5i are independently alkyl; [48] R 6 , R 6a , R 6b , R 6c and R 6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a together with the nitrogen to which they are attached 1 to 4 N in the ring To form a cyclized 5-, 6- or 7-membered heterocycle which may contain 0, S, SO and / or SO 2 heteroatoms; [49] A is 0, S, NH or (CH 2 ) n , where n is 0 to 3; [50] In addition, compounds of formula (I) of the invention as defined above are those wherein A is (CH 2 ) n , wherein n is 0, 1, 2 or 3 or A is O and R 1 , R 2 and R If at least one of 2a is OH or OR 5 , at least one of R 1 , R 2 and R 2a is CF 3 , OCF 3 or OCHF 2 and / or at least one of R 3 and R 4 is CF 3 , —OCHF 2 , -OCF 3 , -CH (OR 5h ) R 6d , CH (OH) R 6c , COR 6b , -CN, -C0 2 R 5b , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, Clues include -SR 5e , -SOR 5f , -SO 2 R 5 g or -SO 2 aryl. [51] Preferred compounds of formula (I) as defined above are those in which A is (CH 2 ) n (where n is 0, 1, 2 or 3) or O and R 1 , R 2 , R 2a , R 3 and R 4 If at least one of is OH or OR 5 , at least one of R 1 , R 2 and R 2a is CF 3 , OCF 3 or OCHF 2 and / or at least one of R 3 and R 4 is CF 3 , —OCHF 2 , -OCF 3 , -CN, -C0 2 R 5b , -CH (OR 5h ) R 6d , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -SO 2 R 5 g , —SO 2 aryl or halogen. [52] Compounds of formula (I) have activity as inhibitors of the sodium dependent glucose transporters found in the intestines and kidneys of mammals, and have diabetes and micro- and macrovascular complications of diabetes (eg, retinopathy, neuropathy and nephropathy). Useful for healing and wound healing. [53] The present invention provides compounds of formula I, pharmaceutical compositions using such compounds, and methods of using such compounds. [54] In addition, according to the present invention, diabetes mellitus, including diabetic complications (including retinopathy, neuropathy, nephropathy and delayed wound healing), in which a compound having a structure of formula (I) is administered to a human patient in need of such treatment, Specifically, the progression or onset of type I diabetes and type II diabetes, and insulin resistance (damage of glucose homeostasis), hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, obesity, hyperlipidemia, including hypertriglyceridemia, syndrome X, Methods of treating or delaying related diseases such as atherosclerosis, and hypertension, and methods of increasing high density lipoprotein levels are provided. [55] Furthermore, according to the method of the present invention, a combination of a compound of formula (I) with another form of therapeutic agent, such as an antidiabetic agent and / or a hyperlipidemic agent, is administered to a patient in need of a therapeutically effective amount, and Provided are methods of treating diabetes and related diseases as defined below. [56] Physical abnormalities, diseases and disorders collectively referred to as "Syndrome X (also known as metabolic syndrome)" are described in Johansson (J. Clin. Endocrinol. Metab., 82, 727-34 (1997)). . [57] As used herein, the term “another form of therapeutic agent” refers to one or more antidiabetic agents (except SGLT2 inhibitors of Formula I), one or more anti-obesity agents, antihypertensives, antiplatelets, anti-atherosclerosis, and / or 1 Species or more lipid lowering agents (including anti-atherosclerosis) are referred to. [58] In the above method of the present invention, the compound of formula (I) of the present invention is one, two or more antidiabetic agents, and / or one, two or more other forms of therapeutic agent (depending on the mode of operation thereof). ) Will be used in a weight ratio of about 0.01: 1 to about 300: 1, preferably about 0.1: 1 to about 10: 1. [59] Preferred are compounds of formula (IA). [60] [61] Where [62] A is CH 2 , O or S and is linked to the meta position relative to the glucoside; [63] R 1 , R 2 and R 2a are independently selected from H, lower alkyl, halogen, OR 5 or OCHF 2 , or two of R 1 , R 2 and R 2a are H, and the rest are lower alkyl, halogen, OR 5 or OCHF 2 ; [64] R 3 and R 4 are independently lower alkyl, OR 5a , -OCHF 2 , -SR 5e , OH, -C0 2 R 5b , -3,4- (OCH 2 O)-, -COR 6b , -CH (OH ) R 6c , -CH (OR 5h ) R 6d , CF 3 , , -SOR 5f , -S0 2 R 5 g , aryl, -NHSO 2 aryl, -NHSO 2 R 5d , COOH, thiadiazole, tetrazole, -OCH 2 aryl, -OCF 3 , Oaryl or H . [65] A is CH 2 ; R 1 is hydrogen, halogen or lower alkyl; R 2 and R 2a are each H; R 3 is H; More preferred are compounds of formula I, wherein R 4 is lower alkyl, -COR 6b , -CH (OH) R 6c , -CH (OR 5h ) R 6d , R 5a O, -OCHF 2 , -OCF 3 or -SR 5e Do. [66] Most preferred are compounds of formula I, having the structure of formula IB. [67] [68] Wherein R 1 is hydrogen, halogen or lower alkyl and R 4 is lower alkyl, R 5a O, —OCHF 2 or —SR 5e . R 1 is linked to the para position with respect to the glucoside bond and R 4 It is preferred that the substituent is linked to the para position. [69] <Detailed Description of the Invention> [70] Compounds of formula (I) of the present invention may be prepared as shown in the following schemes and their descriptions, in which temperatures are indicated in degrees Celsius. [71] As shown in Scheme 1, the compounds of Formula I can be prepared by, for example, 1) Pd / C using a solvent such as MeOH or EtOH, or 2) preferably using a solvent such as EtOAc. It can be prepared by treating with H 2 in the presence of a catalyst such as Pd (OH) 2 . Alternatively, the compound of formula (I) may be prepared by treating the compound of formula (II) with a Lewis acid such as BBr 3 , BCl 3 or BCl 3 · Me 2 S in a solvent such as CH 2 Cl 2 at −78 ° C. Compounds of formula (I) can also be prepared by treating compounds of formula (II) in a solvent such as EtSH containing BF 3 .Et 2 O at 20 ° C. [72] [73] Wherein Bn is benzyl [74] The compound of formula II (which is a new intermediate) is prepared by reacting the compound of formula III with Et in a solvent such as MeCN or MeCN / CH 2 Cl 2 containing Lewis acid, such as BF 3 · Et 2 O, or a solvent such as MeCN at −30 ° C. It can be prepared by treatment with a silane such as 3 SiH or preferably (iPr) 3 SiH. [75] [76] The compound of formula III, which is a new intermediate, may be prepared by coupling a compound of formula IV to a compound of formula V: [77] [78] [79] Compounds of formula IV are activated by treatment with n-BuLi or t-BuLi in a solvent such as THF at −78 ° C. for coupling followed by the addition of lactones of formula V. The preparation of lactones of formula V is described in R. Benhaddou, S Czernecki, et al., Carbohydr. Res., 260 (1994), 243-250. [80] [81] The compound of formula IV wherein A is (CH 2 ) n , wherein n is 1 to 3, is a compound of formula VI at -30 to + 60 ° C. to a Lewis acid such as BF 3 · Et 2 O or TFA. It can be prepared as shown in Scheme 2 by treating with a silane such as Et 3 SiH in a solvent such as MeCN or CH 2 Cl 2 . [82] [83] Compounds of formula (VI) are prepared by coupling bromobenzaldehyde of formula (VII) to organometallic lithium or magnesium derivatives of compounds of formula (VIII), commercially available in solvents such as Et 2 O or THF, using conditions familiar to those skilled in the art. By ring. [84] [85] [86] The compounds of formula (VIII) are commercially available or readily prepared by standard methods known to those skilled in the art. [87] [88] Compounds of formula (I), wherein R 4 is CH (OR 5h ) R 6d , sequentially form compounds of formula (I) wherein R 4 is COR 6b 1) pyridine alone or 1.5 equivalents of CH 2 Cl 2 containing a base such as Et 3 N; Treatment with an acetylating agent such as Ac 2 O in a solvent such as 2) treatment with a reducing agent such as NaBH 4 in a solvent such as EtOH, 3) R 5h Br or R in the presence of a base such as NAH in a solvent such as DMF Treatment with an alkylating agent such as 5h I and 4) alkaline ester hydrolysis conditions such as LiOH in a mixture of THF / MeOH / H 2 O (2: 3: 1). [89] Compounds of formula (I) wherein R 4 is CH (OH) R 6C can be prepared by treating compounds of formula (I) wherein R 4 is COR 6b with a reducing agent such as NaBH 4 in a solvent such as EtOH. [90] R 4 is COR 6b, a compound of formula I R 4 is can be prepared by treatment with a Lewis acid such as BCl 3 or BBr 3 in a solvent such as CH 2 Cl 2 of the compound of the formula II from -78 COR 6b ℃ . [91] Compounds of formula (II) wherein A is CH 2 and R 4 is —COR 6b are commercially available or readily available compounds of formula (IX) including compounds of formula (X) and the two components of Pd (PPh 3 ) 4; It can be prepared as shown in Scheme 3 by coupling by heating in a solvent such as PhMe in the presence of the same catalyst. [92] [93] Wherein Z is Br or Cl. [94] [95] Compounds of formula X (which are new intermediates) can be prepared by treating compounds of formula XI with catalysts such as (Bu 3 Sn) 2 and Pd (Ph 3 P) 4 in a solvent such as toluene. [96] [97] Compound of formula (XI) (which is a new intermediate) is treated with a compound of formula (XII) with a silane such as iPr 3 SiH or Et 3 SiH in a solvent such as MeCN containing Lewis acid such as BF 3 · Et 2 O at −30 ° C. Can be prepared. [98] [99] Compounds of formula XII (which are new intermediates) can be prepared by coupling a compound of formula V with an organolithium obtained when the compound of formula XIII is treated with n-BuLi or t-BuLi in THF at −78 ° C. have. [100] [101] [102] Another synthesis of a compound of formula IV, wherein A is CH 2 (Scheme 4) is carried out in a solvent such as MeCN or CH 2 Cl 2 containing a catalyst such as BF 3 · Et 2 O, or a mixture thereof. This involves reducing with a reducing agent such as Et 3 SiH. [103] [104] Compounds of formula (XIV) can be used to formulate commercially available hydrocarbons of formula (XV) as acid chlorides of formula (XVI) which are readily available in a solvent such as CS 2 containing two equivalents of Lewis acid, such as AlCl 3 or AlBr 3. Friedel-Craft) can be easily prepared by acylation. [105] [106] [107] [108] Compounds of formula (II) wherein A is a single bond can be prepared as shown in Scheme 5 by coupling a compound of formula (XI) with a compound of formula (XVII) or a corresponding boronic acid of formula (XVIII). [109] [110] [111] Coupling involves heating in the presence of a catalyst such as Pd (PPh 3 ) 4 using a solvent such as PhMe / EtOH (3: 1) containing Na 2 CO 3 . Compounds of formula (XVIII) are commercially available or can be prepared by treating compounds of formula (XVII) with BCl 3 in a solvent such as CH 2 Cl 2 . The compound of formula XVII can be prepared by heating the compound of formula XIX with a compound of formula XIX in a solvent such as DMSO containing a catalyst such as PdCl 2 · dppf and a base such as KOAc. [112] [113] [114] [115] Compounds of formula II wherein A is CH 2 and R 2 is OH can be treated by treating a compound of formula XXI with a base such as NaH and then heating the compound of formula IX in a solvent such as PhMe as shown in Scheme 6 below. Can be prepared together. [116] [117] Compounds of formula XXI can be prepared by treating compounds of formula XXII with silanes such as Et 3 SiH or i-Pr 3 SiH in a solvent such as MeCN containing Lewis acid such as BF 3 · Et 2 O at −30 ° C. Can be. [118] [119] Compounds of formula (XXII) can be prepared by coupling a compound of formula (V) with an activated metallized derivative of a compound of formula (XXIII), wherein the activated metallized derivative of compound of formula (XXIII) is NaH, KH or KOtBu Prepared by treatment with a base followed by alkyllithium such as nBuLi or tBuLi in a solvent such as anhydrous THF. [120] [121] [122] Compounds of formula (I) wherein A is O or NH are available commercially by heating the compounds of formula (XXIV) in a solvent such as pyridine containing a base such as Et 3 N, a catalyst such as Cu (OAc) 2 and a molecular sieve By coupling with a compound of Formula XXV, it can be prepared as in Scheme 7 below. [123] [124] [125] Wherein X is O or NH [126] Compounds of formula XXIV (which are new intermediates) may be prepared by treating compounds of formula XXVI with BCl 3 in a solvent such as CH 2 Cl 2 at −78 ° C. [127] [128] Compounds of formula XXVI, which are new compounds, can be prepared by heating compounds of formula XI together with compounds of formula XX in a solvent such as DMSO containing a catalyst such as PdCl 2 · dppf and a base such as KOAc. [129] [130] A compound of formula IV, wherein A is 0 or NH, may be prepared by heating a compound of formula XVIII in a solvent such as pyridine containing a base such as Et 3 N, a catalyst such as Cu (OAc) 2 and a molecular sieve By coupling with a compound, it can be prepared as shown in Scheme 8 below. [131] <Formula XVIII> [132] [133] [134] Wherein X is 0 or NH [135] [136] Compounds of formula IV wherein A is S can be prepared by coupling an aryl disulfide of formula XXVIII to an organolithium obtained by metallizing the compound of formula XIII with n-BuLi or t-BuLi in THF at −78 ° C. have. [137] [138] [139] The following list is a definition of various terms used in the description of the present invention. These definitions apply to the terms as used throughout the specification, either individually or as part of a larger group, unless they are otherwise limited to specific examples. [140] The following abbreviations are used in this specification. [141] Ph = phenyl; Bn = benzyl; [142] t-Bu = tertiary butyl; Me = methyl; [143] Et = ethyl; TMS = trimethylsilyl; [144] TMSN 3 = trimethylsilyl azide; TBS = tert-butyldimethylsilyl; [145] THF = tetrahydrofuran; Et 2 O = diethyl ether; [146] EtOAc = ethyl acetate; DMF = dimethyl formamide; [147] MeOH = Methanol; EtOH = Ethanol; [148] i-PrOH = isopropanol; HOAc or AcOH = acetic acid; [149] TFA = trifluoroacetic acid; i-Pr 2 NEt = diisopropylethylamine; [150] Et 3 N = triethylamine; DMAP = 4-dimethylaminopyridine; [151] NaBH 4 = sodium borohydride; LiAlH 4 = lithium aluminum hydride; [152] n-BuLi = n-butyllithium; Pd / C = palladium on carbon; [153] KOH = potassium hydroxide; NaOH = sodium hydroxide; [154] LiOH = lithium hydroxide; K 2 CO 3 = potassium carbonate; [155] NaHC0 3 = sodium bicarbonate; [156] EDC (or EDC.HCl) or EDCI (or EDCI.HCl) or EDAC = 3-ethyl-3 '-(dimethylamino) propyl-carbodiimide hydrochloride (or 1- (3-dimethylaminopropyl) -3- Ethylcarbodiimide hydrochloride); [157] HOBT or HOBT.H 2 0 = 1-hydroxybenzotriazole hydrate; [158] HOAT = 1-hydroxy-7-azabenzotriazole; [159] Ph 3 P = triphenylphosphine; Pd (OAc) 2 = palladium acetate; [160] (Ph 3 P) 4 Pd o = tetrakis triphenylphosphine palladium; [161] Ar = argon; N 2 = nitrogen; [162] min = minutes; h or hr = hours; [163] L = liters; mL = milliliters; [164] Μl = microliters; g = grams; [165] mg = milligrams; mol = mol; [166] mmol = millimoles; meq = milliequivalents; [167] RT = room temperature; sat or sat'd = saturation; [168] aq. = Aqueous; TLC = thin layer chromatography; [169] HPLC = high performance liquid chromatography; [170] LC / MS = high performance liquid chromatography / mass spectroscopy; [171] MS or Mass Spec = mass spectroscopy; NMR = nuclear magnetic resonance; [172] mp = melting point; dppf = diphenylphosphinoferrocene. [173] Unless otherwise indicated, as used herein alone or as part of another group, the term "lower alkyl" includes both straight and branched chain hydrocarbons containing 1 to 8 carbons, and herein As used alone or as part of another group, the terms "alkyl" and "alk" refer to 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1, in the general chain. And both straight and branched chain hydrocarbons containing from 8 to 8 carbons, examples of which are methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4 , 4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, various branched chain isomers thereof, and halo (e.g., F, Br, Cl, or I), or CF 3, alkyl, alkoxy, aryl, aryloxy, aryl (aryl) or diaryl, Arylalkyl, arylalkyloxy, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkyloxy, optionally substituted amino, hydroxy, hydroxyalkyl, acyl, alkanoyl, heteroaryl, hetero Aryloxy, cycloheteroalkyl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, There are such groups containing 1 to 4 substituents, such as thiols, haloalkyl, trihaloalkyl and / or alkylthio. [174] Unless otherwise indicated, as used herein, alone or as part of another group, the term "cycloalkyl" refers to a saturated or partially unsaturated (one or two double bond) containing one to three rings; Cyclic hydrocarbon groups (including monocyclic alkyls, bicyclic alkyls and tricyclic alkyls having from 3 to 20, preferably from 3 to 10, carbon atoms forming the ring) Hydrocarbon groups can be associated with one or two aromatic rings as described for aryl, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, Cyclohexenyl, [175] [176] And optionally include halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, And 1 to 4 substituents, such as thiols and / or alkylthios, and / or any alkyl substituents. [177] As used herein, alone or as part of another group, the term "cycloalkenyl" refers to 3 to 12 carbons, preferably 5 to 10 carbons, and 1 or 2 double bonds. The cyclic hydrocarbon which has is called. Examples of cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl. [178] As used herein alone or as part of another group, the term “alkanoyl” refers to alkyl linked to a carbonyl group. [179] Unless otherwise indicated, the term "lower alkenyl" as used herein per se or as part of another group refers to a straight or branched chain radical having 2 to 8 carbons, and the term "alkenyl "Is used in this specification as such or as part of another group, from 2 to 20 carbons, preferably from 2 to 12 carbons, more preferably from 2 to 8 carbons in the ordinary chain Refers to straight-chain or branched radicals having the formula: vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-hep Such as tenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecaterienyl, etc. Containing 1 to 6 double bonds in the usual chain, 1 to 4 substituents, ie halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkoxy Aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, alkylthio and / or It may be optionally substituted with any of the alkyl substituents disclosed. [180] Unless otherwise indicated, as used herein per se or as part of another group, the term "lower alkynyl" refers to a straight or branched chain radical having 2 to 8 carbons, and as used herein As used by itself or as part of another group, the term "alkynyl" usually has from 2 to 20 carbon atoms in the chain, preferably from 2 to 12 carbon atoms, more preferably from 2 to 8 carbon atoms and one Straight or branched chain radicals with triple bonds, for example 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2 -Heptinyl, 3-heptinyl, 4-heptinyl, 3-octinyl, 3-noninyl, 4-decynyl, 3-undecynyl, 4-dodecynyl, and the like, which are 1-4 Substituents, ie halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cyclohetero Optionally substituted with chel, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and / or alkylthio, and / or any alkyl substituents disclosed herein. . [181] As used herein, alone or as part of another group, the terms "arylalkyl", "arylalkenyl" and "arylalkynyl" refer to alkyl, alkenyl and alkynyl having aryl substituents as described above. It is called a group. [182] An alkyl group, as defined above, having a single bond for bonding to another group at two different carbon atom positions is referred to as an "alkylene" group and may be optionally substituted as defined above for "alkyl". [183] Alkenyl groups and alkynyl groups as defined above, each having a single bond for bonding at two different carbon atom positions, are referred to as "alkenylene groups" and "alkynylene groups", respectively, "alkenyl" and "alky Optionally substituted as defined above for "Nyl". [184] As defined herein, a suitable alkylene group, alkenylene group or alkynylene group, or (CH 2 ) m or (CH 2 ) p (where p is 1 to 8, preferably 1 to 5, m Is 1 to 5, preferably 1 to 3, alkylene group, alkenylene group or alkynylene group) is optionally 1, 2 or 3 alkyl, alkenyl, halogen, cyano, hydroxy, alkoxy, Substituents including amino, thioalkyl, keto, C 3 -C 6 cycloalkyl, alkylcarbonylamino or alkylcarbonyloxy. [185] Examples of (CH 2 ) m or (CH 2 ) p , alkylene, alkenylene and alkynylene are -CH 2 -,-CH 2 CH 2- , [186] [187] Can be mentioned. [188] As used herein alone or as part of another group, the terms "halogen" or "halo" refer to chlorine, bromine, fluorine and iodine, with chlorine or fluorine being preferred. [189] The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium, and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum. [190] Unless otherwise indicated, as used herein alone or as part of another group, the term “aryl or Aryl” refers to monocyclic and bicyclic having 6 to 10 carbons in the ring moiety. Aromatic groups (eg, phenyl, or naphthyl including 1-naphthyl and 2-naphthyl) and refer to carbocyclic or heterocyclic rings (eg, aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings, For example Optionally include one to three additional rings associated with hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, Cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, aryl Thio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino, wherein amino is one or two Substituents, which substituents are alkyl, aryl or any other aryl compound mentioned in the definitions), thiols, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, al Kylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, Arylsulfinylalkyl, arylsulfonylamino and arylsulfonaminocarbonyl and / or optionally substituted via available carbon atoms having one, two or three groups selected from any of the alkyl substituents disclosed herein. . [191] Unless otherwise indicated, as used herein, alone or as part of another group, the term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" means any of the above linked to an oxygen atom. Alkyl, aralkyl or aryl groups. [192] Unless indicated otherwise, as used herein alone or as part of another group, the term “substituted amino” refers to amino substituted with one or two substituents, which substituents are the same or different. Examples include alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl and thioalkyl have. These substituents may be further substituted with carboxylic acids and / or any alkyl substituents as disclosed above. Amino substituents also include 1-pyrrolidinyl, 1-piperidinyl, 1-azinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy with the nitrogen atom to which they are attached 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-pipera Form genyl, 1-pyrrolidinyl, 1-piperidinyl or 1-azinyl. [193] Unless otherwise indicated, as used herein alone or as part of another group, the terms "lower alkylthio", "alkylthio", "arylthio" or "aralkylthio" are linked to a sulfur atom And any of the above alkyl, aralkyl or aryl groups. [194] Unless otherwise indicated, as used herein alone or as part of another group, the terms "lower alkylamino", "alkylamino", "arylamino" or "arylalkylamino" are linked to a nitrogen atom And any of the above alkyl, aryl or arylalkyl groups. [195] Unless otherwise indicated, as defined herein, the term "acyl" as used herein or as part of another group is carbonyl. Refers to organic radicals linked to groups, examples of acyl groups include any alkyl substituents attached to carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cyclohetero Alkanoyl and the like. [196] Unless otherwise indicated, as used herein alone or as part of another group, the term “cycloheteroalkyl” refers to a five-, six- or seven-membered saturated or partially unsaturated ring, wherein the ring Comprises from 1 to 2 heteroatoms (eg nitrogen, oxygen and / or sulfur), said hetero atoms being carbon atoms or heteroatoms, possibly optionally a linking group (CH 2 ) p (where p is 1 , 2 or 3), and examples of such 5, 6 or 7 membered saturated or partially unsaturated rings include [197] Etc. Such groups include 1 to 4 substituents, for example alkyl, halo, oxo and / or any alkyl substituents disclosed herein. In addition, any cycloheteroalkyl ring may be associated with a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring. [198] Unless otherwise indicated, as used herein, alone or as part of another group, the term “heteroaryl” refers to one, two, three or four heteroatoms (eg, nitrogen, oxygen). Or sulfur) containing 5 or 6 membered aromatic rings, which are linked to aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings (e.g. benzothiophenyl or indolyl) and form possible N-oxides. Include. Heteroaryl groups may optionally include 1 to 4 substituents, for example any of the alkyl substituents disclosed above. Examples of heteroaryl groups include [199] Etc. [200] As used herein alone or as part of another group, the term “cycloheteroalkylalkyl” refers to a cycloheteroalkyl group as defined above, connected to the (CH 2 ) p chain via a C atom or a heteroatom. . [201] As used herein, alone or as part of another group, the term “heteroarylalkyl” or “heteroarylalkenyl” refers to a — (CH 2 ) p via C atom or heteroatom, as defined above. A heteroaryl group as defined above, linked to a chain, alkylene or alkenylene. [202] The term "5-, 6- or 7-membered carbocyclic ring or heterocycle" as used herein refers to a cycloalkyl or cycloalkenyl group as defined above, or a heteroaryl group or cycloheteroaryl group as defined above, for example thiadia Zaol, tetrazole, imidazole or oxazole. [203] The term "polyhaloalkyl" as used herein includes from 2 to 9, preferably from 2 to 5 halo substituents, for example F or Cl, preferably F, as defined above. Examples of the "alkyl" group include CF 3 CH 2 , CF 3 or CF 3 CF 2 CH 2 . [204] The term "polyhaloalkyloxy" as used herein includes two to nine, preferably two to five halo substituents, for example F or Cl, preferably F, as defined above. Examples of the "alkoxy" or "alkyloxy" group include CF 3 CH 2 O, CF 3 O or CF 3 CF 2 CH 2 O. [205] As used herein, the term “prodrug ester” refers to alkyl, at least one hydroxyl of the compound of formula (I) using methods known to those skilled in the art to prepare acetates, pivalates, methylcarbonates, benzoates, and the like. Esters and carbonates formed by reacting with alkoxy or aryl substituted acylating agents. There are also prodrug esters known in the art for carboxylic acid and phosphate esters, such as methyl, ethyl, benzyl esters and the like. [206] Examples of such prodrug esters include [207] This includes. [208] Said prodrug esters, in which the compound of formula I is in acidic form, are alkali metal salts (eg lithium, nadium or potassium), alkaline earth metal salts (eg calcium or magnesium), as well as zinc or aluminum, and other cations such as For example ammonium, chlorine, diethanolamine, lysine (D or L), ethylenediamine, t-butylamine, t-octylamine, tris- (hydroxymethyl) aminomethane (TRIS), N-methyl glucoseamine (NMG Pharmaceutically acceptable salts such as triethanolamine and dehydrobiethylamine. [209] All stereoisomers of the compounds of the invention are contemplated in the form of mixtures, pure or substantially pure. Compounds of the present invention may have an asymmetric center at any carbon atom including any one R substituent. Thus, the compounds of formula (I) may exist in the form of enantiomers or diastereomers, or mixtures thereof. Racemates, enantiomers or diastereomers may be used as starting materials in the production process. When preparing diastereomers or enantiomeric products, they can be separated by conventional methods, for example by chromatography or fractional crystallization. [210] If desired, the compounds of formula (I) may be used in combination with one or more other types of antidiabetic agents and / or one or more other types of therapeutic agents, which may be administered orally or in the same dosage form or in separate oral dosage forms. Can be. [211] Other types of antidiabetic agents that may optionally be used in combination with SGLT2 inhibitors of Formula I include one or two, including insulin secretagogues or insulin sensitizers, preferably other antidiabetic agents with mechanisms of action different from SGLT2 inhibitors. Species, three or more antidiabetic or antihyperglycemic agents, and may be a biguanide, sulfonyl urea, glucosidase inhibitor, PPAR γ agonist such as thiazolidinedione, aP2 inhibitor, PPARα / γ dual agonist Dipeptidyl peptidase IV (DP4) inhibitors, and / or meglitinides, as well as insulin, glucagon-like peptide-1 (GLP-1), PTP1B inhibitors, glycogen phosphorylase inhibitors, and / or glucose- 6-phosphatase inhibitors. [212] Other types of therapeutic agents that can optionally be used in combination with SGLT2 inhibitors of Formula I include anti-obesity agents, antihypertensive agents, antiplatelets, anti- atherosclerosis and / or lipid lowering agents. [213] In addition, the SGLT2 inhibitors of Formula (I) may optionally be used in combination with therapeutic agents for diabetic complications. These diabetic complications include PKC inhibitors and / or AGE inhibitors. [214] The use of the compounds of formula (I) in combination with one, two, three or more antidiabetic agents is greater than the effect of using each of these agents alone and the additional antihyperglycemia obtained by these agents It is considered greater than the sum of the effects. [215] Other antidiabetic agents may be oral antihyperglycemic agents, preferably biguanides such as metformin or phenformin, or salts thereof, preferably metformin HCl. [216] If the other antidiabetic agent is biguanide, the compound of formula (I) will be used in a weight ratio of about 0.01: 1 to about 100: 1, preferably about 0.1: 1 to about 5: 1 relative to biguanide. [217] In addition, other antidiabetic agents are preferably sulfonyl ureas such as glyburide (also known as glibenclamide), glymepiride (disclosed in US Pat. No. 4,379,785), glyphide, glyclazide or Chlorpropamide, other known sulfonylureas or other antihyperglycemic agents (acting on the ATP dependent channels of β-cells), glyburide and glipidide are preferred, administered in the same or separate oral dosage forms Can be. [218] The compound of formula (I) will be used in a weight ratio of about 0.01: 1 to about 100: 1, preferably about 0.2: 1 to about 10: 1, relative to sulfonyl urea. [219] In addition, the oral antidiabetic agent may be a glucosidase inhibitor, for example acarbose (disclosed in US Pat. No. 4,904,769) or miglitol (disclosed in US Pat. No. 4,639,436), the same or separate oral It may be administered in a dosage form. [220] The compound of formula (I) will be used in a weight ratio of about 0.01: 1 to about 100: 1, preferably about 0.5: 1 to about 50: 1, relative to the glucosidase inhibitor. [221] Compounds of formula (I) can be used in combination with PPAR γ agonists such as thiazolidinedione, oral antidiabetics or other insulin sensitizers (which have insulin-sensitive effects in NIDDM patients), for example troglitazone (Warner-Lambert's lezuline) (Rezulin®, disclosed in U.S. Patent No. 4,572,912), Rosiglitazone (SKB), Pioglitazone (Takeda), Mitsubishi MCC-555 (disclosed in U.S. Patent No. 5,594,016), Glaxo-Welcome GL-262570, Englitazone (CP-68722, Pfizer) or Darglitazone (CP-86325, Pfizer), Isaglitazone (MIT / J & J), JTT-501 (JPNT / P & U) (Glaxo-Welcome) ), L-895645 (Merck), R-119702 (Sankyo / WL), NN-2344 (Dr. Reddy / NN), or YM-440 (Yamanouchi), preferably in combination with rosiglitazone and pioglitazone. [222] The compound of formula (I) will be used in a weight ratio of about 0.01: 1 to about 100: 1, preferably about 0.2: 1 to about 10: 1 relative to thiazolidinedione. [223] Oral antidiabetic agents sulfonyl urea and thiazolidinedione can be incorporated into a single tablet with a compound of formula (I) in an amount of less than about 150 mg. [224] In addition, compounds of formula (I) can be used in antihyperglycemic agents such as insulin, or glucagon-like peptide-1 such as GLP-1 (1-36) amide, GLP-1 (7-36) amide, GLP-1 (7-37) (GLP-1) (disclosed in Habener, US Pat. No. 5,614,492, the disclosure of which is incorporated herein by reference), as well as in combination with AC2993 (Amylen) and LY-315902 (Lilly) It can be used and can be administered by injection, intranasal, or via a transdermal or oral device. [225] If present, metformin, sulfonyl urea, for example glyburide, glymepiride, glypiride, glypizide, chlorpropamide and glyclazide, and the glucosidase inhibitor acarbose or miglitol or insulin (injection For administration, or for pulmonary, oral or oral administration) may be used in amounts and dosages as indicated in the Physician's Desk Reference (PDR) with the formulations described above. [226] If present, metformin or a salt thereof is used in an amount of about 500 to about 2000 mg daily, and may be administered in a single dose or in divided doses of one to four times daily. [227] If present, thiazolidinedione antidiabetic agents may be used in amounts of about 0.01 to about 2000 mg daily, and may be administered in a single dose or in divided doses of one to four times daily. [228] If present, insulin may be used in the formulations, amounts, and dosages as indicated in the Physician Desktop Reference. [229] If present, the GLP-1 peptide may be administered as an oral oral formulation, intranasally, or as described in US Pat. Nos. 5,346,701 (TheraTech), 5,614,492 and 5,631,224, which are incorporated herein by reference. Parenteral administration. [230] Other antidiabetic agents also include PPAR α / γ dual agents such as AR-HO39242 (Astra / Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck), as well as Murakami et al. PPAR alpha and PPAR gamma as disclosed in “A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation-Activated Receptor Alpha.” Effects on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats ", [Diabetes 47, 1841-1847 (1998)] and U.S. Provisional Application No. 60 / 155,400 (filed Sep. 22, 1999, Representative Document LA29). use. Preference is given to compounds which are indicated as preferred in the above-mentioned US application. [231] Other antidiabetic agents are disclosed, for example, in US Application Ser. No. 09 / 391,053, filed Sep. 7, 1999, and US Provisional Application No. 60 / 127,745, filed Apr. 5, 1999, Representative Document LA27 *. It may be an aP2 inhibitor used at a dosage as disclosed in this application. Preference is given to compounds which are indicated as preferred in this application. [232] Other antidiabetic agents are WO 99/38501, WO 99/46272, WO 99/67279 (PROBIODRUG), WO 99/67278 (Probiodrugs) and WO 99 /. DP4 inhibitors as disclosed in 61431 (Probiodrugs), Hughes et al., NVP-DPP728A (1-[[[as described in Biochemistry, 38 (36), 11597-11603, 1999). 2-[(5-cyanopyridin-2-yl) amino] ethyl] amino] acetyl] -2-cyano- (S) -pyrrolidine), (Novartis) (preferred), TSL-225 (tri Propofyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Yamada et al., Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540) ), 2-cyanopyrroli as disclosed in Ashworth et al., Bioorg. & Med. Chem. Lett., Vol. 6, No. 22, pp 1163-1166 and 2745-2748 (1996). Died and 4-cyanopyrrolidide, and may be used in dosages as disclosed in the above references. [233] The meglitinide that may optionally be used in combination with the compounds of formula (I) of the present invention may be repaglinide, nateglinide or KAD1229 (PF / Kissei), with repaglinide being preferred. [234] SGLT2 inhibitors of Formula (I) are about 0.01: 1 to about 100: 1, preferably about 0.2: 1 to about 10: 1 for meglitinide, PPAR γ agonist, PPAR α / γ dual agonist, aP2 inhibitor or DP4 inhibitor Will be used in the weight ratio. [235] Hyperlipidemic or lipid lowering agents that may optionally be used in combination with the compounds of formula (I) of the present invention include one, two, three or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, frbric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na + / bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants and / or nicotinic acid, and derivatives thereof. [236] As used herein, MTP inhibitors include US Pat. Nos. 5,595,872, 5,739,135, 5,712,279, 5,760,246, 5,827,875, and 5,885,983, and US Application No. 09 / 175,180 (1998). MTP inhibitors disclosed in the October 20 application, currently issued by US Pat. No. 5,962,440). Preferred respective MTP inhibitors disclosed in each of the above patents and applications are preferred. All content of these US patents and applications are incorporated herein by reference. [237] Hyperlipidemia includes mevastatin and related compounds (disclosed in US Pat. No. 3,983,140), lovastatin (mebinolin) and related compounds (disclosed in US Pat. No. 4,231,938), paravastatin and related compounds ( US Pat. No. 4,346,227), and simvastatin and related compounds (as disclosed in US Pat. Nos. 4,448,784 and 4,450,171), but may be HMG CoA reductase inhibitors. In addition, the hyperlipidemic agent may be a compound disclosed in US Provisional Application Nos. 60 / 211,594 and 60 / 211,595. Other HMG CoA reductase inhibitors that may be used herein include fluvastatin (disclosed in US Pat. No. 5,354,772), cerivastatin (disclosed in US Pat. No. 5,006,530 and 5,177,080), atorvastatin (US Pat. No. 4,681,893, No. 5,273,995, No. 5,385,929 and No. 5,686,104), Athavastatin (Nissan / Sankyo, Nisvastatin (NK104), US Patent No. 5,011,930) ), Shionogi-Astra / Zeneca bisastatin (ZD-4522) (disclosed in US Pat. No. 5,260,440), and statin-related compounds (disclosed in US Pat. No. 5,753,675), Pyrazole homologues of mevalonolactone derivatives (disclosed in US Pat. No. 4,613,610), indene homologues of mevalonolactone derivatives (disclosed in PCT application WO 86/03488), 6- [2- (substituted- Pyrrole-1-yl) -alkyl) pyran-2-one and its derivatives (disclosed in US Pat. No. 4,647,576) ), SC-45355 (3-substituted pentanedioic acid derivatives) dichloroacetate, an imidazole homologue of mevalonolactone (disclosed in PCT Application WO 86/07054), 3-carboxy- 2-hydroxy-propane-phosphonic acid derivatives (disclosed in French Patent No. 2,596,393), 2,3-disubstituted pyrrole, furan and thiophene derivatives (disclosed in European Patent Application No. 0221025), mevalonolactone Naphthyl homologue (disclosed in US Pat. No. 4,686,237), octahydronaphthalene (disclosed in US Pat. No. 4,499,289), keto homolog of mevinolin (lovastatin) (disclosed in European Patent Application No. 0,142,146 A2), and Quinoline and pyridine derivatives (as disclosed in US Pat. Nos. 5,506,219 and 5,691,322), including but not limited to. [238] In addition, phosphinic acid compounds useful for the inhibition of HMG CoA reductase suitable for use herein are disclosed in GB 2205837. [239] Suitable squalene synthetase inhibitors for use herein include α-phosphono-sulfonate (disclosed in US Pat. No. 5,712,396), Bill et al., J. Pat. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinyl-methyl) phosphonates, as well as other known squalene synthetase inhibitors, for example US Pat. Nos. 4,871,721 and 4,924,024. And Biller, SA, Neuenschwander, K., Ponpipom, MM, and Poulter, CD. Current Pharmaceutical Design, 2, 1-40 (1996) )] But is not limited to this. [240] Other squalene synthetase inhibitors suitable for use herein also include terpenoid pyrophosphates (P. Ortiz de Montellano et al., J. Med. Chem., 1977, 20, 243-249), farnesyl diphosphate homologue A and prisqualene pyrophosphate (PSQ-PP) homologues (Corey and Volante, J. Am. Chem. Soc., 1976, 98 , Disclosed in 1291-1293), phosphinylphosphonates (reported in McClard, RW et al. (JACS, 1987, 109, 5544)) and cyclopropane (Capson, TL) (PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary). [241] Other hyperlipidemic agents suitable for use herein include fibric acid derivatives such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, cipropibrate, clinfibrate, and the like, and probucol and related compounds (US Patent No. 3,674,836) (probucol and gemfibrozil are preferred), bile acid sequestrants such as cholestyramine, cholestipol and DEAE-Sepadex (Secholex®) ), Polyxide® (Policexide®)), as well as lipostavill (Rhone-Poulenc), Eisai E-5050 (N-substituted ethanolamine derivatives), imanicil (HOE-402), Tetrahydroleafstatin (THL), Istig Mastanylphosphorylcholine (SPC, Roche), Aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (Azulene Derivative) , Melinamide (Sumitomo), Sandoz 58-035, Ah American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly (diallylmethylamine) derivatives (USA Patents 4,759,923), 4-group amine polys (diallyldimethylammonium chloride) and ionene (as disclosed in US Pat. No. 4,027,009), and other known serum cholesterol lowering agents. Do not. [242] Other hyperlipidemic agents include, for example, Drugs of the Future 24, 9-15 (1999), (Avasimibe); ["The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al., Atherosclerosis (Shannon, Irel). (1998), 137 (1), 77-85; ["The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc. Drug Rev. (1998), 16 (1), 16-30; ["RP 73163: a bioavailable alkylsulfinyl-diphenylimidazloe ACAT inhibitor", Smith, C., et al., Bioorg. Med. Chem. Lett. (1996), 6 (1), 47-50; ["ACAT inhibitor: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al., Editor (s): Ruffolo, Robert R., Jr.]; Hollinger, Mannfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla .; ["ACAT inhibitor: potential anti-atherosclerotic agents", Sliskovic et al., Curr. Med. Chem. (1994), 1 (3), 204-25; ["inhibitor of acyl-CoA: cholesterole O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The water-soluble ACAT inhibitor with lipid-regulating activity.Inhibitors of acyl-CoA: cholesterol acyltransferase (ACAT). a series of substituted N-phenyl-N '-[(1-phenylcyclopentyl) methyl] ureas with enhanced hypocholesterolemic activity ", Stout et al., Chemtracts: Org. Chem. (1995), 8 (6), 359-62, or TS-962 (Taisho Pharmaceutical Co. Ltd)). [243] Hyperlipidemic agents may be enhancers of LD2 receptor activity, such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly). [244] Hyperlipidemic agents are cholesterol absorption inhibitors, preferably SCH48461 from Schering-Plough, as well as Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 ( 1998). [245] The hyperlipidemic agent can be, for example, an ileal Na + / bile acid cotransporter inhibitor as disclosed in Drugs of the Future, 24, 425-430 (1999). [246] Preferred hyperlipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and rosuvastatin. [247] The contents of the above-mentioned US patents are incorporated herein by reference. Amounts and dosages will be used as indicated in the Physician Desktop Reference and / or Patents set forth above. [248] The compounds of formula (I) of the invention will be used in a weight ratio of about 500: 1 to about 1: 500, preferably about 100: 1 to about 1: 100, relative to the hyperlipidemic agent (if present). [249] Dosage should be carefully adjusted according to the age, weight and physical condition of the patient, as well as the route of administration, dosage form, and regimen and desired outcome. [250] Dosages and formulations for hyperlipidemia will be as disclosed in the various patents and applications above. [251] If applied, dosages and formulations for other hyperlipidemic agents to be used will be as set forth in the latest edition of the Physician Desktop Reference. [252] For oral administration, satisfactory results can be obtained by using the MTP inhibitor once to four times daily in an amount of about 0.01 to about 500 mg / kg, preferably about 0.1 to about 100 mg / kg. [253] Preferred oral dosage forms, such as tablets or capsules, in an amount of about 1 to about 500 mg, preferably about 2 to about 400 mg, more preferably about 5 to about 250 mg over once to four times daily. Will contain the MTP inhibitor. [254] For oral administration, satisfactory results indicate that HMG CoA reductase inhibitors, such as pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin, are indicated in the dosing table reference, for example about 1 To 2000 mg, preferably from about 4 to about 200 mg. [255] Squalene synthase inhibitors will be used in dosages ranging from about 10 mg to about 2000 mg, preferably from about 25 mg to about 200 mg. [256] Preferred oral dosage forms, such as tablets or capsules, contain HMG CoA reductase inhibitor in an amount of about 0.1 to about 100 mg, preferably about 5 to about 80 mg, more preferably about 10 to about 40 mg. something to do. [257] Preferred oral dosage forms, such as tablets or capsules, will contain the squalene synthetase inhibitor in an amount of about 10 to about 500 mg, preferably about 25 to about 200 mg. [258] In addition, other hyperlipidemia agents include 15-lipoxygenase (15-LO) inhibitors (disclosed in WO 97/12615), such as benzimidazole derivatives, and 15-LO inhibitors (disclosed in WO 97/12613). ), Isothiazolone (disclosed in WO 96/38144), and 15-LO inhibitor (Sendobry et al., "Attenuation of diet-induced atherosclerosis inrabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties, "Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al.," 15-lipoxygenase and its Inhibition: A Novel Therapeutic Target for Vascular Disease ", Current Pharmaceutical Design, 1999, 5, 11-20), as well as lipoxygenase inhibitors. [259] The compound of formula I and the hyperlipidemic agent can be used together in the same oral dosage form or in separate oral dosage forms taken simultaneously. [260] The compositions described above may be administered in dosages as described above in a single dose or in divided doses from one to four times daily. For patients, it would be reasonable to start with a lower dosage formulation and gradually prescribe a higher dosage formulation. [261] Preferred hyperlipidemic agents are pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and rosuvastatin. [262] If the other type of therapeutic agent that may optionally be used with the SGLT2 inhibitor of Formula I is one, two, three or more anti-obesity agents, the anti-obesity agents include beta 3 adrenergic agents, lipase inhibitors, serotonin (and dopamine). ) Reuptake inhibitors, thyroid receptor beta drugs, appetite suppressants, NPY antagonists, leptin homologs and / or MC4 agonists. [263] Beta 3 adrenergic agents that can be used in combination with a compound of formula (I) are AJ9677 (Takeda / Dainippon), L750355 (Merck), or CP331648 (Pfizer), or other known beta 3 agents (US Pat. No. 5,541,204, Copper 5,770,615, 5,491,134, 5,776,983 and 5,488,064), preferably AJ9677, L750, 355 and CP331648. [264] Lipase inhibitors which may optionally be used in combination with compounds of formula (I) may be orlistat or ATL-962 (Alizyme), with orlistat being preferred. [265] Serotonin (and dopamine) reuptake inhibitors which may optionally be used in combination with compounds of formula (I) may be sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), with sibutramine and topiramate being preferred. [266] The thyroid receptor beta compounds that can optionally be used in combination with compounds of formula (I) include thyroid receptor ligands (WO 97/21993 (U. Cal SF), WO 99/00353 (KaroBio) and GB 98/284425 (KaroBio), compounds of carobio application being preferred. [267] Appetite reducing agents which may optionally be used in combination with a compound of formula (I) may be dexampetamine, phentermine, phenylpropanolamine or marginol, with dexampetamine being preferred. [268] The various anti-obesity agents described above can be used in the same dosage form or in different dosage forms as the compounds of formula (I) in dosages and regimes as are generally known in the art or in PDR. [269] Examples of antiplatelet agents that may optionally be used in the combinations of the present invention include absiksimab, ticlopidine, eftibivatide, dipyridamole, aspirin, anaglylides, tyropiban and / or clopidogrel. [270] Examples of antihypertensive agents that may optionally be used in the combinations of the present invention include ACE inhibitors, calcium antagonists, alpha-blockers, diuretics, central agonists, angiotensin-II antagonists, beta-blockers and vasopeptidase inhibitors. [271] Examples of ACE inhibitors include ricinopril, enalapril, quinapril, benazepril, posinopril, ramipril, captopril, enalapril, moexifril, trandolapril and perindopril; Examples of calcium antagonists include amlodipine, diltiazem, nifedipine, verapamil, ferodipine, nisoldipine, ispadipine and nicardipine; Examples of alpha-blockers include terrazosin, doxazosin and prazosin; Examples of diuretics include hydrochlorothiazide, torasemide, furosemide, spironolactone and indafamid; Examples of central agents include clonidine and guanfacin; Examples of angiotensin-II antagonists include losartan, valsartan, irbesartan, candesartan and telmisartan; Examples of beta-blockers include metoprolol, propranolol, atenolol, carvedolol and sotalol; Examples of vasopeptidase inhibitors include omapatrilat and gemopatrilat. [272] In carrying out the methods of the invention, it is possible to use pharmaceutical compositions which contain a compound of formula (I) together with a pharmaceutical vehicle or diluent in the presence or absence of another antidiabetic and / or another antihyperlipidemic or other type of therapeutic agent. Can be. Pharmaceutical compositions can be formulated using conventional solid or liquid vehicles or diluents, and pharmaceutical additives of the type appropriate for the desired mode of administration. The compounds may be administered by oral route to a mammal, including humans, monkeys, dogs, and the like, for example in the form of tablets, capsules, granules or powders, or parenterally in the form of injectable preparations, or intranasally. Or in a transdermal patch. The dosage for adults is preferably 10 to 2,000 mg daily, and can be administered in a single dose or divided into 1 to 4 daily doses. [273] A typical injectable preparation is prepared by aseptically containing 250 mg of the compound of formula (I) in a vial, sterile lyophilized and sealed. For use, the contents of the vial are mixed with 2 mL of saline solution to prepare an injectable preparation. [274] SGLT2 inhibitor activity of the compounds of the present invention can be measured using the evaluation system described below. [275] Evaluation of SGLT2 Activity [276] MRNA sequences for human SGLT2 (GenBank # M95549) were cloned using standard molecular biology techniques via reverse transcription and amplification from human kidney mRNAs. cDNA sequences were stably transduced into CHO cells, and clones were assessed SGLT2 activity as virtually as described in Ryan et al. (1994). Evaluation of the inhibition of SGLT2 activity of cloned cell lines was carried out with the following adjustments in effect as described in Rihanna's literature. Cells were 75,000 or 30,000 per well in F-12 nutrient mixture (Ham's F12), 10% fetal bovine serum, 300 μg / mL Geneticin and penicillin-streptomycin in 96-well plates for 2-4 days. Incubated with cells. In confluence, cells were washed twice with 10 mM Hepes / Tris pH 7.4, 137 mM N-methyl-D-glucamine, 5.4 mM KCl, 2.8 mM CaCl 2 , 1.2 mM MgS0 4 . Cells were then 10 μM [ 14 C] AMG, and 10 μM inhibitor in Hepes / Tris (pH 7.4) 10 mM at 37 ° C. (final DMSO concentration was 0.5%), NaCl 137 mM, KCl 5.4 mM, Incubated with CaCl 2 2.8 mM, MgSO 4 1.2 mM. The assay was taken by year and quenched with ice cold 1 × PBS (containing 0.5 mM floridine), and the cells were then lysed with 0.1% NaOH. After addition of the MicroScint scintillation solution, the cells were shaken for 1 hour, and then [ 14 C] AMG was weighed with a TopCount scintillation counter. Controls were performed with or without NaCl. To determine EC 50 values, 10-fold enrichment inhibitors were used over 2 log intervals within the appropriate reaction range and averaged over 3 plates. [277] Ryan MJ, Johnson G, Kirk J, Fuerstenberg SM, Zager RA and Torok-Storb B, 1994. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney International 45: 48-57. [278] The following examples show preferred embodiments of the present invention. All temperatures are given in degrees Celsius unless otherwise indicated. [279] <Example 1> [280] [281] A. 3-Bromo-4'-ethylbenzylhydrol [282] After stirring dry Mg flakes (4.4 g, 0.178 mol) overnight under argon atmosphere, 100 mL of anhydrous Et 2 O was added, followed by p-bromoethylbenzene (22 g, 0.119 mol) in 20 mL of Et 2 O. Add for 1 hour. (If the reaction did not start, 0.5 mL of 1,2-dibromoethane was added). After stirring overnight, m-bromobenzaldehyde (11 g, 0.06 mol) in 20 mL of Et 2 O was slowly added. The resulting pale solution was monitored by HPLC for 4-6 hours to determine when it was terminated. After quenching with saturated aqueous NH 4 Cl, the reaction was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The resulting yellow oil was eluted by chromatography on silica gel using 5% EtOAc / hexanes, and non-polar impurities were eluted with 3-bromo-4'-ethylbenzhydr as a pale yellow oil using 7-9% EtOAc / hexanes. 12.4 g (71%) of the roll eluted. [283] B. 3-Bromo-4'-ethyldiphenylmethane [284] To a stirred solution of 3-Bromo-4'-ethylbenzhydrol (12.4 g, 0.0426 mol) of Part A in 120 mL of MeCN was added BF 3 .Et 2 O (6.04 g, 0.0426 mol). Then Et 3 SiH (9.9 g, 0.852 mol) was added. The dark reaction was stirred at −30 ° C. for 1 hour and then slowly warmed to −5 ° C. When completion was confirmed by TLC, the reaction was quenched by the addition of saturated aqueous K 2 CO 3 . After addition of 100 mL of H 2 O, the mixture was extracted three times with Et 2 O. The combined organic layers were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 3-bromo-4'-ethyldiphenylmethane (11.17 g, 95%) was obtained as a pale yellow oil, which was used without further purification. [285] C. [286] [287] To a -78 ° C stirred solution of 3-Bromo-4'-ethyldiphenylmethane (10.9 g, 0.04 mol) of Part B in 100 mL of anhydrous THF under argon atmosphere was added 25.7 mL of 1.7 M t-BuLi in hexane for 20 minutes. Was added. After 1 hour, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (23.5 g, 0.0437 mol) in 30 mL of THF was added for 15 minutes. The solution was stirred at -78 ° C for 1 h and then quenched with saturated aqueous NH 4 Cl. After warming to 20 ° C., the reaction was diluted twice with EtOAc and then washed with H 2 O followed by brine. Drying over Na 2 SO 4 and concentration on a rotary evaporator gave 29.2 g of the desired title lactol as colorless syrup, which was then used without further purification. [288] D. [289] [290] To the -30 ° C agitation solution of the Lactol (29.1 g, 0.04 mol) of Part C in 100 mL of MeCN was added BF 3 · Et 2 O (5.62 g, 0.04 mol) and then Et 3 SiH (9.21 g, 0.08 mol). ) Was added. After 2 hours, when completion of the reaction was confirmed by TLC, saturated aqueous K 2 CO 3 was added and the suspension was stirred at 20 ° C. for 1 hour, then diluted with H 2 O and Et 2 O. After extraction three times with Et 2 O, the combined organic layers were washed with brine, dried over Na 2 SO 4 and concentrated on a rotary evaporator to give 28.3 g of a pale yellow syrup. After elution of the nonpolar impurities by chromatography on silica gel with 5% EtOAc / hexanes, the beta anomer was slowly eluted, followed by the alpha anomer. Fractions enriched in beta anomer were further purified by hexane or recrystallized from EtOH to give 6 g of the desired titled Tetra-O-benzyl C-glucoside. (Note that when Et 3 SiH is a reducing agent, a 5: 1 beta / alpha anomer mixture is obtained, whereas when replaced with iPr 3 SiH, a 30: 1 mixture is obtained). [291] E. [292] [293] A solution of tetra-0-benzyl C-glucoside (2.4 g, 3.35 mmol) of Part D in EtOAc (100 mL) containing 10% Pd (OH) 2 / C (0.35 g) overnight under H 2 1 atmosphere. Stirred. After confirming that the reaction was complete by HPLC, the catalyst was filtered off and the solvent removed on a rotary evaporator to yield 1.1 g (92%) of the desired beta C-glucoside as a white crystalline solid. [294] HPLC retention time: 7.04 min, Purity: 100%, YMC S5 C-18 4.6 x 50 mm column, 2.5 mL / min, detection by 220 nM: 8 minute gradient after 0-100% B, then 5 minutes at 100% B maintain. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 . [295] [296] <Example 2> [297] [298] A. 3-Bromo-4'-methoxybenzhydrol [299] 117 mL of 2.56 M n-BuLi (0.3 mol) in hexane was added to the -78 ° C stirred solution of m-dibromobenzene (70.9 g, 0.3 mol) in 200 mL of dry THF under argon atmosphere for 10 minutes. After 30 minutes, p-methoxybenzaldehyde (27.2 g, 0.02 mol) in 50 mL of THF was added for 20 minutes. The solution was stirred at −78 ° C. for 1 h (after completion of the reaction by TLC) and then quenched with saturated aqueous NH 4 Cl. After warming to 20 ° C., the reaction was diluted twice with EtOAc and then washed with H 2 O and brine. After drying over Na 2 SO 4 and concentration on a rotary evaporator, 103 g of 3-bromo-4'-methoxybenzhydrol was obtained as a yellow oil which was then used without further purification. [300] B. 3-Bromo-4'-methoxydiphenylmethane [301] To Et 3 SiH (64 mL, 0.4 mol) was added to the crude 3-bromo-4'-methoxybenzhydrol (103 g, 0.2 mol) -40 ° C stirring solution in 300 mL of MeCN, BF 3 · Et 2 O (27.7 g, 0.2 mol) was added. When completion was confirmed by TLC, the reaction was quenched by the addition of saturated aqueous K 2 CO 3 (25 mL). After addition of 100 mL of H 2 O, the mixture was extracted three times with EtOAc. The combined organic layers were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, the title crude 3-bromo-4'-methoxydiphenylmethane (92 g) was chromatographed on silica gel using 9% EtOAc / hexanes to elute 17 g of pure compound. Afterwards a less pure fraction eluted. [302] C. [303] [304] To a -78 ° C stirred solution of 3-Bromo-4'-methoxydiphenylmethane (9.6 g, 0.035 mol) of Part B in 50 mL of anhydrous THF under argon atmosphere was added 14 mL of 2.5 M n-BuLi in hexane for 5 minutes. Was added. After 30 min stirring, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (12.5 g, 0.023 mol) in 20 mL of THF was added for 10 minutes. The solution was stirred at -78 ° C for 1 hour, at which time the reaction was complete by TLC analysis. After quenching with saturated aqueous NH 4 Cl (25 mL), warmed to 20 ° C. and the reaction was diluted with EtOAc (200 mL). The organic layer was washed with H 2 O and brine. Dry over Na 2 SO 4 and concentrate on a rotary evaporator to give the desired title lactol by chromatography on silica gel using 12.5% EtOAc / hexanes, eluting more than 90% purity of 8.1 g of lactol, followed by 80% purity. Above 9.7 g of lactol eluted. [305] D. [306] [307] Et 3 SiH (3.42 mL, 0.04 mol) was added to a -40 ° C stirred solution of the Lactol (7.8 g, 0.019 mol) of Part C in 100 mL of MeCN, followed by BF 3 .Et 2 O (1.37 mL, 0.02 mol). ) Was added. After 1 hour, when TLC confirmed the reaction was complete, saturated aqueous K 2 CO 3 (10 mL) was added and the suspension was stirred at 20 ° C. for 1 hour and then extracted three times with EtOAc. The combined organic layers were diluted with H 2 O and brine, dried over Na 2 SO 4 and concentrated on a rotary evaporator to give 8 g of crude product. After elution of the nonpolar impurities by chromatography on silica gel with 5% EtOAc / hexanes, 0.92 g of pure title β-tetra-O-benzyl C-glucoside was eluted, and 6.5 g of both anomers were eluted. [308] E. [309] [310] The two fractions of the compound of Part D in EtOAc (12.5 mL / g of Part D compound g) were hydrogenated individually on 10% Pd (OH) 2 (2 wt.%) Overnight under H 2 1 atmosphere. After filtration and solvent removal, the hydrogenated product of the mixed fractions was purified by preparative HPLC using a YMC S10 reverse phase column. From the combined material, 1.85 g of pure β-anomer was obtained as a white solid. [311] HPLC retention time: 6.04 min, Zorbox C-18 4.6 x 75 mm column, 2.5 mL / min, detection with 220 nM: Hold at 100% B for 3 min after gradient of 0-100% B for 8 min. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 . [312] [313] <Example 3> [314] [315] A. [316] [317] To an -78 ° C stirred solution of m-dibromobenzene (12.6 g, 53 mmol) in 50 mL of dry THF under argon atmosphere was added 20 mL of 2.56 M n-BuLi (51 mmol) in hexane for 10 minutes. After 40 minutes, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (12 g, 22 mmol) in 30 mL of THF was added for 15 minutes. The solution was stirred at −78 ° C. for 1 h (after completion of the reaction by TLC) and then quenched with saturated aqueous NH 4 Cl (40 mL). After warming to 20 ° C., the reaction was diluted twice with EtOAc, then washed with H 2 O and brine. After drying over Na 2 S0 4 and concentration on a rotary evaporator, 20 g of the title crude lactol were obtained as an oil which was then used without further purification. [318] B. [319] [320] Et 3 SiH (7.8 mL, 45 mmol) was added to a stirred solution of crude lactol (20 g, 0.2 mol) of Part A in 60 mL of MeCN, followed by BF 3 · Et 2 O (4.2 mL, 22 mmol) was added slowly for 20 minutes. After 1 hour, when complete by TLC was confirmed, the reaction was quenched by addition of saturated aqueous K 2 CO 3 (25 mL) and the mixture was extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The resulting oil was triturated with 50 mL of hexane and solids precipitated when left for 1 hour. The material was collected by filtration, washed twice with cold hexane and air dried to yield 8.9 g of the desired title β-m-bromophenyl-C-glucoside. [321] C. [322] [323] Hexabutyldistanne in β-m-bromophenyl-C-glucoside (1.39 g, 2 mmol), Pd (PPh 3 ) 4 (70 mg, 0.06 mmol) and toluene (10 mL) of the above part B. A solution of phosphorus (2.724 g, 6 mmol) was heated with stirring at 80 ° C. under argon atmosphere for 15 h. After removal of toluene using a rotary evaporator, the residue was chromatographed on silica gel using EtOAc / hexanes (12: 1) to elute the desired title aryl stanne (761 mg), followed by mixed fractions. This eluted, an additional 92 mg of pure title stanne in the second column was obtained with a total yield of 48%, recovering 230 mg of β-m-bromophenyl-C-glucoside starting material of Part B above. . [324] D. [325] [326] The mixture of stanine (2.66 g, 3 mmol), p-trifluoromethoxybenzyl chloride (1.04 g, 6 mmol) and Pd (PPh 3 ) 4 (100 mg, 0.09 mmol) of Part E was added under argon. Reflux in THF for 15 hours. After removal of THF by rotary evaporator, the residue was chromatographed on silica gel using hexanes / EtOAc (10: 1) to elute 1.3 g of the desired titled tetrabenzyl ether. [327] E [328] . [329] Conversion to the final free glucoside was achieved by stirring Pd (OH) 2 (15 mg) in EtOAc (3 mL) and 295 mg of tetrabenzyl ether of Part D for 15 hours under H 2 1 atm. The title compound (104 mg) was filtered, chromatographed with preparative HPLC and isolated by removal of solvent. [330] HPLC retention time: 7.21 min, Zorbox C-18 4.6 x 75 mm column, 2.5 mL / min, detected by 220 nM: Hold for 8 min at 100% B after a gradient of 0-100% B. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 . [331] [332] <Example 4> [333] [334] A. [335] [336] Β-m-bromophenyl-C-glucoside (3.0 g, 4.41 mmol) and Pd (PPh 3 ) 4 (153 mg, 0.13 mmol), and hexabutyl of Example 3 Part B in anhydrous toluene (5 mL) A mixture of distanane (6.0 g, 13.2 mmol) was heated at 88 ° C. for 3 hours with stirring under an argon atmosphere, whereupon TLC analysis indicated that the reaction was 90% complete. The reaction was terminated after a total of 5 hours. After toluene was removed using a rotary evaporator, the residue was chromatographed using EtOAc / hexane (1: 8) on silica gel to elute 2.95 g of the desired aryl stanne. [337] B. [338] [339] A mixture of stanine (2.66 g, 3 mmol), p-methylthiobenzyl chloride (1.04 mg, 6.0 mmol) and tetrakis (triphenylphosphine) palladium (100 mg, 0.09 mmol) of Part A was prepared in an argon atmosphere. Under reflux for 15 h in THF (5 mL). After removing THF with a rotary evaporator, the residue was eluted by chromatography using hexanes / EtOAc (6: 1) on silica gel to give the desired titled tetra-0-benzyl ether, followed by the title compound Ph 3 P containing tetra 600 mg of -O-benzyl ether was eluted. [340] C. [341] [342] 1 M BCl 3 / CH 2 Cl 2 (6 mL, 8 mmol) was added to a stirred solution of tetrabenzyl ether (295 mg, 0.4 mmol) of Part B in CH 2 Cl 2 (0.25 mL) under argon. Add over 5 minutes. After 30 minutes, when TLC analysis indicated completion of the reaction, 30 mL of 2: 1 CH 2 Cl 2 / PhMe was added and 2 mL of MeOH was added. The volume was reduced in half using a rotary evaporator and 10 mL of MeOH was added. After repeating this process three times, all volatiles were removed under vacuum. The residue was chromatographed on silica gel with 5% MeOH / CH 2 Cl 2 to elute 143 mg of the desired glucoside in 90% purity. Further purification of this material by reverse phase preparative HPLC gave 104 mg of the final desired glucoside. [343] HPLC retention time: 6.69 min, detection at Zorbox C-18 4.6 × 75 mm column, 2.5 mL / min, 220 nM; Hold at 100% B for 3 minutes after a gradient of 0 to 100% B for 8 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 P0 4 . [344] [345] Example 5 [346] [347] A. [348] [349] To a stirred suspension of 60% NaH (180 mg, 4.5 mmol) in THF (7 mL) under argon atmosphere was added 2-bromophenol (350 μl, 3 mmol). After stirring for 15 minutes, the reaction was cooled to -78 ° C and 1.4 M t-BuLi / hexane (2.36 mL, 3.3 mmol) was added dropwise. After 10 minutes, the solution was passed through a cannula into a -78 ° C stirred solution of 2,3,4,6-tetra-0-benzyl-β-D-glucolactone (1.62 g, 3.0 mmol) in THF (5 mL). Moved. After 15 minutes saturated NH 4 Cl / H 2 O was slowly added to quench the reaction, then warmed to 20 ° C. and 200 mL of EtOAc was added. The organic layer was washed successively with H 2 O and brine, dried over MgSO 4 and concentrated. Chromatography using hexanes / EtOAc (3: 1) on silica gel gave 390 mg of the desired title lactol. [350] B. [351] [352] To a stirred mixture (4 mL) of 3: 1 MeCN / CH 2 Cl 2 containing L-tolhol (390 mg, 0.62 mmol) of Part A at −30 ° C., Et 3 SiH (197 μl, 1.23 mmol) and BF 3. Et 2 O (78 μl, 0.62 mmol) was added. After 1 h the reaction was quenched by addition of 1 mL saturated K 2 CO 3 , warmed to 20 ° C. and diluted with 100 mL EtOAc. The organic layer was washed successively with H 2 O and brine, dried over MgSO 4 and concentrated. Chromatography using hexanes / EtOAc (3: 1) on silica gel gave 269 mg of the desired phenolic C-glucoside. [353] C. [354] [355] To an PhMe solution of Phenol (139 mg, 0.22 mmol) of Part B (1.1 mL) under argon atmosphere was added 60% NaH (11 mg, 0.27 mmol). After 10 minutes, 4-methylbenzyl bromide (46 mg, 0.25 mmol) in solid state was added to the blue solution and then heated at 80 ° C. for 3.5 hours until the reaction was complete by TLC analysis. After cooling and addition of aqueous NH 4 Cl solution, the reaction was diluted with EtOAc. The organic layer was washed successively with H 2 O and brine, dried over MgSO 4 and concentrated. Chromatography using hexanes / EtOAc (5: 1) on silica gel gave 71 mg of tetra-0-benzylglucoside of the title desired. [356] D. [357] [358] Subsequent hydrocracking of the tetra-0-benzyl glucoside of Part C on Pd / C in MeOH under 1 atm H 2 gives the final title product, which is obtained by MeOH / H 2 O (45-90 on a C18 reversed phase column). %) Was purified by preparative HPLC using over 10 minutes to elute the desired β-C-glucoside (2 mg). [359] HPLC retention time: 6.754 min, purity 100%, YMC S3 ODS 4.6x50 mm, 2.5 mL / min, detection at 220 nM; Hold for 5 minutes at 100% B after a gradient of 0 to 100% B for 8 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 P0 4 . [360] [361] <Example 6> [362] [363] A. p-chloromethylacetophenone [364] Tributylphosphine (406 mg, 2.29 mMol) was added to a stirred solution of p-chloromethylbenzoyl chloride (390 mg, 2.06 mmol) in 8 mL THF at -20 ° C under argon atmosphere. The resulting yellow solution was stirred at −20 ° C. to −15 ° C. for 20 minutes, after which 3M methyl magnesium bromide in ether (2.1 mmol) was added portionwise to give a red solution which became orange after 10 minutes. The reaction was quenched by addition of aqueous 1N HCl solution. After dilution with H 2 O, The mixture was extracted three times with EtOAc, washed with H 2 0, dried over Na 2 SO 4. 171 mg (50%) of p-chloromethylacetophenone was eluted by chromatography on silica gel with 5% EtOAc / hexanes. [365] B. [366] [367] Example 3 Stanane (300 mg, 0.33 mmol) described in Part C, p-chloromethylacetophenone (114 mg, 0.66 mmol), Pd (PPh 3 ) 4 (20 mg, 0.09 mmol), triphenylphosphine A mixture of oxide (180 mg, 0.65 mmol) and K 2 CO 3 (75 mg, 0.55 mmol) was heated to 70 ° C. in THF (0.3 mL) for 16 h under argon atmosphere. After removal of THF by rotary evaporator, the residue was eluted by chromatography using hexanes / EtOAc (20: 1 to 10: 1) on silica gel (170 mg, 70%). [368] C. [369] [370] After cooling a solution of the tetrabenzyl ether of Part B (60 mg, 0.08 mmol) in CH 2 Cl 2 (5 mL) under argon atmosphere to −78 ° C., 0.8 mL of 1 M BCl 3 in CH 2 Cl 2 is added. It was. After stirring at −78 ° C. for 1 hour, a second 0.8 mL portion of 1 M BCl 3 was added to the stirred solution. After an additional hour, 0.5 mL of PhMe was added and 0.5 mL of MeOH was added dropwise. The volatiles were removed using a rotary evaporator and the process was repeated after adding 3 mL of a mixture of CH 2 Cl 2 / MeOH (2: 1). The resulting residue was chromatographed on silica gel eluting with 5% MeOH / EtOAc to give 20 mg of 67% yield of tetraol final product. [371] HPLC retention time: 2.35 min, purity 100%, YMC S3 ODS 4.6x50 mm, 2.5 mL / min, detection at 220 nM; Hold for 4 minutes at 100% B after a gradient of 0 to 100% B for 4 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 P0 4 . [372] [373] <Example 7> [374] [375] A stirred solution of Example 6 final product (15 mg, 0.04 mmol) in 5 mL of EtOH was cooled to −20 ° C. and NaBH 4 (5 mg, 0.13 mmol) was added. When the reaction was completed by TLC analysis after 20 minutes, the reaction was quenched with a few drops of saturated NH 4 Cl aqueous solution. After removing the volatiles, the residue was chromatographed on silica gel. Elution with 5% MeOH / EtOAc gave 10 mg (67%) of the desired product. [376] HPLC retention time: 5.2 min, purity 100%, YMC S3 ODS 4.6x50 mm, 2.5 mL / min, detection at 220 nM; Hold for 5 minutes at 100% B after a gradient of 0 to 100% B for 8 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 P0 4 . [377] [378] <Example 8> [379] [380] A. 5-Bromo-2-methylbenzoic acid [381] A mixture of o-toluic acid (28 g, 206 mmol), iron powder (0.74 g, 13 mmol) and Br 2 (42 g, 260 mmol) was stirred at 0 ° C for 2 h. At this point of about 40% of the reaction, the reaction was diluted with 25 mL of CH 2 Cl 2 to facilitate stirring. The reaction was then heated at 45 ° C. for 16 hours to complete the reaction. Upon cooling, the reaction was diluted with CH 2 Cl 2 , washed twice with 10% NaHS0 3 and once with brine and then dried over Na 2 SO 4 . After removing the volatiles, the residue comprising a mixture of 5-bromotoluic acid to 3-bromotoluic acid (2: 1) was recrystallized from 95% EtOH to give 14.4 g of 5-bromo-2-methylbenzoic acid. Obtained. [382] B. 5-Bromo-2-methyl-4'methoxybenzophenone [383] Two drops of DMF were added to a stirred suspension of 5-bromo-2-methylbenzoic acid (1.29 g, 6 mmol) in 12 mL of CH 2 Cl 2 containing oxalyl chloride (8 mmol). After the vigorous gas evolution had ceased, the reaction was stirred for 6 hours, after which the volatiles were removed using a rotary evaporator. After dissolving crude 5-bromo-2-methylbenzoyl chloride in 15 mL of CS 2 , the stirred mixture was cooled to 4 ° C., anisole (0.7 g, 6.6 mmol) was added and AlCl 3 (1.7 g, 12 mmol) was added. After the reaction was warmed to 20 ° C. over 1 hour, the reaction was stirred for 15 hours and the reaction was quenched with 1N HCl. The suspension was then diluted with 50 mL of H 2 0 and stirred until all solids dissolved. This mixture was extracted three times with EtOAc. The combined organic extracts were washed once with 1N HC1, H 2 O, NaHCO 3 aqueous solution and brine, and then dried over Na 2 SO 4 . After removing the volatiles, the resulting tan solid was recrystallized from 95% EtOH to give 1.6 g of 5-bromo-2-methyl-4'-methoxybenzophenone. [384] C. 5-Bromo-2-methyl-4'-methoxydiphenylmethane [385] Et 3 SiH (2.5 mL, 15.5 mmol), BF 3 Et 2 O (1.3 mL, 10 mmol) and 5-bromo-2-methyl- in 11 mL of a mixture of CH 2 Cl 2 / MeCN (1: 4). A solution of 4'-methoxybenzophenone (1.6 g, 5.25 mmol) was stirred at 20 ° C overnight. When 5% in the starting ketone remained when analyzed by HPLC, the solution was heated to 40 ° C. for 1 hour and then quenched with 10% NaOH. After diluted with H 2 O, the reaction was extracted three times with EtOAc. The combined organic layers were washed twice with H 2 O and once with brine and then dried over Na 2 SO 4 . After removing the volatiles, the residue was chromatographed using hexane on silica gel to elute 5-bromo-2-methyl-4'-methoxydiphenylmethane (1.4 g, 95%) as a colorless oil. [386] D. [387] [388] 1.8 M n of hexane to a -78 ° C stirred solution of 5-Bromo-2-methyl-4'-methoxydiphenylmethane (0.43 g, 1.5 mmol) of Part C in anhydrous THF (7 mL) under argon atmosphere. 0.9 mL of BuLi was added dropwise. After 2 hours, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (0.88 g, 1.6 mmol) in 3 mL of THF was added over 1 minute. The solution was stirred at -78 ° C for 2 hours and then quenched with saturated aqueous NH 4 Cl solution. After warming to 20 ° C., the reaction was diluted twice with H 2 O and then extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 1.1 g of the desired title lactol as a colorless syrup were obtained and used for the next reaction without further purification. [389] E. [390] [391] To a stirred solution of L-tolhol (1.1 g, 1.47 mmol) of Part D in 30 mL of MeCN, iPr 3 SiH (0.7 g, 4.5 mmol) was added followed by BF 3 · Et 2 O (0.38 g, 2.6 mmol). It was. After 3 hours at −40 to −30 ° C., TLC analysis showed the reaction to be complete. Saturated aqueous K 2 CO 3 solution was added and the suspension was stirred at 20 ° C. for 1 h and then diluted with H 2 O and EtOAc. The combined organic layers from three EtOAc extractions were washed with brine, dried over Na 2 SO 4 and concentrated using a rotary evaporator to give 1.2 g of a pale yellow syrup. Chromatography eluted with 10% EtOAc / hexanes on silica gel, followed by elution of the desired beta C-arylglucoside (0.54 g). [392] F. [393] [394] A solution of tetra-0-benzyl C-glucoside (515 mg, 0.7 mmol) of Part E in EtOAc (10 mL) containing 10% Pd (OH) 2 / C (80 mg) was added under 1 atmosphere H 2 . Stir overnight. HPLC analysis indicated that the reaction was complete, and then the catalyst was filtered off, the solvent was removed on a rotary evaporator to yield a white crystalline solid, which was further purified by preparative HPLC using a C 18 reversed phase column to give a colorless syrup. 220 mg of the desired beta C-glucoside was obtained. [395] HPLC retention time: 6.43 min, 100% purity, YMC S5 C-18 4.6 x 50 mm column, 2.5 mL / min, detection at 220 nM; After a gradient of 0-100% B for 8 minutes, hold at 100% B for 5 minutes. Solvent A: 10% MeOH / H 2 0 + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 0 + 0.2% H 3 PO 4 . [396] [397] Example 9 [398] A. 5-Bromo-2-methyl-4'-hydroxydiphenylmethane [399] [400] 10 mL of -78 ° C CH 2 Cl 2 stirred solution of 5-bromo-2-methyl-4'-methoxydiphenylmethane (1.O g, 3.4 mmol) (for the preparation, see Example 8, Part C) To 4.12 mL of 1M BBr 3 / CH 2 Cl 2 was added. After 2 hours, the reaction was maintained at -40 ° C. for 20 hours, and HPLC analysis showed that no starting material ether remained. The reaction was quenched with aqueous NaOH solution, extracted three times with CH 2 Cl 2 , washed with brine and then dried over Na 2 SO 4 . After removal of the volatiles, 0.84 g of 5-bromo-2-methyl-4'-hydroxydiphenylmethane was obtained, which was used without further purification. [401] B. 5-Bromo-2-methyl-4'-benzyloxydiphenylmethane [402] 5-Bromo-2-methyl-4'-hydroxydiphenylmethane (735 mg, 2.65 mmol), benzyl bromide (548 mg, 3.2 mmol) and K 2 CO 3 (732 mg, 5.3 mmol) of Part A above. 10 mL of DMF solution containing was stirred overnight. The reaction was then heated at 60 ° C. for 6 hours to convert from 80% to 100%. After diluting with H 2 O, the reaction was extracted three times with EtOAc. The combined EtOAc layers were washed with H 2 0 and brine and then dried over Na 2 SO 4 . After the solvent was removed in vacuo, the residue was chromatographed on silica gel with 3% EtOAc / hexane to elute 785 mg of colorless syrup, 5-bromo-2-methyl-4'-benzyloxydiphenylmethane. [403] C. [404] [405] 1.9 M n in hexane to a -78 ° C stirred solution of 5-Bromo-2-methyl-4'-benzyloxydiphenylmethane (0.43 g, 1.2 mmol) of Part B in anhydrous THF (7 mL) under argon atmosphere. 0.68 mL of BuLi was added dropwise. After 30 minutes, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (0.7 g, 1.3 mmol) in 3 mL of THF was added over 1 minute. The solution was stirred at −78 ° C. for 0.75 hours and then quenched with saturated aqueous NH 4 Cl solution. After warming to 20 ° C., the reaction was diluted twice with H 2 O and then extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 0.96 g of the desired title lactol, a colorless syrup, was obtained and used in the next reaction without further purification. [406] D. [407] [408] To a stirred −30 ° C. solution of the Lactol (0.96 g, 1.16 mmol) of Part C in 10 mL of MeCN was added iPr 3 SiH (0.37 g, 2.3 mmol) followed by BF 3 · Et 2 O (0.2 g, 1.4 mmol). Added. After 3 h at −40 to −30 ° C., saturated aqueous K 2 CO 3 aqueous solution was added and the suspension was stirred at 20 ° C. for 1 h and then diluted with H 2 O and EtOAc. The combined organic layers from three EtOAc extractions were washed with brine, dried over Na 2 SO 4 and concentrated using a rotary evaporator to give 1.2 g of a pale yellow syrup. Chromatography eluted with 9% EtOAc / hexanes on silica gel and the desired beta C-arylglucoside (0.26 g) eluted with 10% EtOAc / hexanes. [409] E. [410] [411] A solution of the penta-0-benzyl C-glucoside (255 mg, 0.31 mmol) of Part D in EtOAc (10 mL) containing 10% Pd (OH) 2 / C (65 mg) was added at 1 atmosphere H 2 . Stirred HPLC analysis showed the reaction to be complete, then the catalyst was filtered off and the solvent was removed on a rotary evaporator to yield 115 mg of a white crystalline solid, which was used without further purification. [412] F. [413] [414] A threaded tube comprising a magnetic stirrer, 4 mL of iPrOH and the phenolic C-glucoside (80 mg, 0.16 mmol) of Part E above was cooled to −78 ° C. and then CHClF 2 1.5 by gas condensation. g was added. 3 mL of 25% NaOH aqueous solution was added, then the tube was sealed with a Teflon stopper and heated to 70 ° C. for 2 hours. As a result of HPLC analysis, the reaction contained a 2: 3 mixture of starting material phenol to the desired ether (an effort to increase conversion by increasing reaction time was unsuccessful). After cooling, the pH was adjusted to 2 by adding sufficient 1N HCl and then most of the volatiles were removed using a rotary evaporator. The residue was dissolved in MeOH / H 2 O (2: 1) and then YMC S5 C 18 reversed phase column (20 × 100 mm) using a MeOH aqueous solution (45% to 90%) in a linear gradient for 10 minutes at 20 mL per minute. Purification by preparative HPLC equipped with) gave 40 mg of the desired phenolic ether. [415] HPLC retention time: 6.6 min, 95% purity, YMC S5 C-18 4.6 x 50 mm column, 2.5 mL / min, detection at 220 nM; After a gradient of 0-100% B for 8 minutes, hold at 100% B for 5 minutes. Solvent A: 10% MeOH / H 2 0 + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 [416] [417] <Example 10> [418] [419] A. 5-Bromo-2-methyl-4'-thiomethylbenzophenone [420] AlCl 3 (535 mg, 4 mmol) was added crude 5-bromo-2-methylbenzoyl chloride (466 mg, 2 mmol) (for preparation, see Example 8, Part B) and thioanisole (270 mg, 2.3 mmol) was added to 5 mL of CS 2 4 ° C stirred solution. The reaction was warmed to 20 ° C. over 1 h, then stirred for 2 h and quenched with 1N HCl. The suspension was then diluted with 50 mL of H 2 0 and stirred until all solids dissolved. The mixture was extracted three times with EtOAc. The combined organic extracts were washed once with 1N HCl, H 2 O, NaHCO 3 aqueous solution and brine, and then dried over Na 2 SO 4 . After removing the volatiles, the residue was chromatographed on silica gel using 15% EtOAc / hexane to elute 450 mg of 5-bromo-2-methyl-4'-thiomethylbenzophenone as a white solid. [421] B. 5-Bromo-2-methyl-4'-thiomethyldiphenylmethane [422] Et 3 SiH (0.45 mL, 2.85 mmol), BF 3 · Et 2 O (0.3 mL, 2.4 mmol) in 3 mL of a CH 2 Cl 2 / MeCN (1: 9) mixture, and 5-bromo- of Part A above. A solution of 2-methyl-4'-thiomethylbenzophenone (450 mg, 1.4 mmol) was stirred at 20 ° C overnight. After quenching with 10% NaOH and diluted with H 2 0, the reaction was extracted three times with EtOAc. The combined organic layers were washed twice with H 2 O, once with brine and then dried over Na 2 SO 4 . After removing the volatiles, the residue was chromatographed on silica gel using 5% EtOAc / hexane to elute 416 mg of colorless oil, 5-bromo-2-methyl-4'-thiomethyldiphenylmethane. [423] C. [424] [425] 1.8 M n-BuLi in hexane to a -78 ° C stirred solution of 5-Bromo-2-methyl-4'-thiomethyldiphenylmethane (200 mg, 0.65 mmol) of Part B in 10 mL of dry THF in argon atmosphere. 0.42 mL was added dropwise. After 2 hours, the solution was canned using a cannula with a stirred solution of 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (0.88 g, 1.6 mmol) in 5 mL of THF. Moved. The solution was stirred at -78 ° C for 2 hours and then quenched with saturated aqueous NH 4 Cl solution. After warming to 20 ° C., the reaction was diluted twice with H 2 O and then extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 550 mg of the desired title lactol as colorless syrup were obtained and used in the next reaction without further purification. [426] D. [427] [428] To the -40 ° C agitation solution of the Lactol (550 mg, 0.72 mmol) of Part C in 6 mL of MeCN was added iPr 3 SiH (0.22 mL, 1.0 mmol) followed by BF 3 Et 2 O (0.11 mL, 0.8 mmol). It was. After 1.5 hours at −40 to −30 ° C., TLC analysis showed that when the reaction was complete, saturated aqueous K 2 CO 3 aqueous solution was added, the suspension was stirred at 20 ° C. for 1 hour, and then H 2 0 And diluted with EtOAc. The combined organic layers from three EtOAc extractions were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. 240 mg of the desired beta C-arylglucoside was eluted by chromatography of the residue with 9% EtOAc / hexane as eluent on silica gel. [429] E. [430] [431] A solution of tetra-0-benzyl C-glucoside (70 mg, 0.1 mmol) of part D in EtSH (1.5 mL) containing BF 3 · Et 2 O (0.24 mL, 2 mmol) at 20 ° C. for 2 hours. Was stirred. After 1 hour more, 0.12 mL of BF 3 · Et 2 O was added and the reaction was complete. The reaction was quenched by the slow addition of 0.4 mL of pyridine and then diluted with aqueous NH 4 Cl solution. The combined organic layers from three EtOAc extracts were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The residue was purified by preparative HPLC using a C 18 reversed phase column and then lyophilized to give 20 mg of the desired beta C-glucoside as white lyophilisate. [432] HPLC retention time: 3.8 min, purity 95%, YMC S5 C- 18 4.6 x 50 mm column, 2.5 mL / min, detection at 220 nM; Hold for 4 minutes at 100% B after a gradient of 0-100% B for 4 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 0 + 0.2% H 3 P0 4 . [433] [434] <Example 11> [435] A. 5-Bromo-2-chloro-4'-thiomethylbenzophenone [436] [437] Two drops of DMF were added dropwise to a stirred suspension of commercial 5-bromo-2-chlorobenzoic acid (506 mg, 2.12 mmol) in 10 mL of CH 2 Cl 2 containing oxalyl chloride (2.4 mmol). After strong gas evolution had ceased, the reaction was stirred for 1.5 hours and then volatiles were removed using a rotary evaporator. After dissolving crude 5-bromo-2-chlorobenzoyl chloride in 8 mL of CS 2 , the stirred mixture was cooled to 4 ° C., followed by thioanisole (260 mg, 2.12 mmol) followed by AlCl 3 (566 mg, 4.25 mmol) was added. The reaction was warmed to 20 ° C. over 1 h and then stirred for 20 h and then quenched with 1N HCl. The suspension was then diluted with 50 mL of H 2 0 and stirred until all solids dissolved. The mixture was extracted three times with EtOAc. The combined organic extracts were washed with 1N HCl, H 2 O, NaHCO 3 aqueous solution and brine and then dried over Na 2 SO 4 . After removal of the volatiles, 710 mg of crude 5-bromo-2-chloro-4'-thiomethylbenzophenone was obtained without further purification. [438] B. 5-Bromo-2-chloro-4'-thiomethyldiphenylmethane [439] Et 3 SiH (1.4 mL, 8.8 mmol), BF 3 Et 2 O (0.83 mL, 6.6 mmol) in 10 mL of a CH 2 Cl 2 / MeCN 1: 4 mixture and 5-bromo-2-chloro of Part A above. A solution of -4'-thiomethylbenzophenone (710 mg, 2.1 mmol) was stirred at 20 ° C for 2 hours. After quenching with 10% NaHCO 3 and diluted with H 2 0, the reaction was extracted three times with EtOAc. The combined organic layers were washed twice with H 2 O, once with brine and then dried over Na 2 SO 4 . After removing the volatiles, the residue was chromatographed on silica gel using 5% EtOAc / hexanes to elute 630 mg of colorless oil, 5-bromo-2-chloro-4'-thiomethyldiphenylmethane. [440] C. [441] [442] 1.5 M n in hexane to -78 ° C stirred solution of 5-Bromo-2-chloro-4'-thiomethyldiphenylmethane (200 mg, 0.61 mmol) of Part B in anhydrous THF (6 mL) under argon atmosphere. 0.48 mL of BuLi was added dropwise. After 35 minutes, the solution was transferred by cannula to a -78 ° C stirred solution of 2,3,4,6-tetra-0-benzyl-β-D-glucolactone (361 mg, 0.67 mmol) in 5 mL of THF. The solution was stirred at −78 ° C. for 1.5 h and quenched with saturated aqueous NH 4 Cl. Warm to 20 ° C, the reaction was diluted 2-fold with H 2 0 and extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . Concentrated using a rotary evaporator, and 250 mg of the desired title lactol was eluted by chromatography on silica gel using 20% EtOAc / hexanes. [443] D. [444] [445] To a 30 ° C. stirred solution of the Lactol (250 mg, 0.32 mmol) of Part C in 5 mL of MeCN was added iPr 3 SiH (0.10 mL, 0.56 mmol) followed by BF 3 · Et 2 O (0.048 mL, 0.38 mmol). . After 0.5 h at −30 ° C., when TLC indicates the reaction is complete, saturated aqueous NaHCO 3 is added and the suspension is stirred at 20 ° C. for 1 h and diluted with H 2 O and EtOAc. The combined organic layers from three EtOAc extracts were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The residue was chromatographed on silica gel using 9% EtOAc / hexane as eluent to elute 200 mg of the desired beta C-arylglucoside. [446] E. [447] [448] A solution of tetra-0-benzyl C-glucoside (60 mg, 0.1 mmol) of part D in EtSH (2 mL) containing BF 3 · Et 2 O (0.24 mL, 2 mmol) at 20 ° C. for 3 hours. Was stirred. To the reaction was quenched by the slow addition of 0.4 mL of pyridine and diluted with aqueous NH 4 Cl. The combined organic layers from three EtOAc extracts were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The residue was purified by preparative HPLC using a C 18 reversed phase column and lyophilized to yield 21.5 mg of the desired beta C-glucoside as a white lyophilisate. [449] HPLC retention time: 3.96 min, purity 95%, YMC S5 C-18 4.6x50 mm column, 2.5 mL / min, detection at 220 nM; Hold for 4 minutes at 100% B after a gradient of 0-100% B for 4 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 . [450] [451] <Example 12> [452] [453] A. 5-Bromo-2-chloro-4'-methoxybenzophenone [454] Two drops of DMF were added to a stirred solution of commercial 5-bromo-2-chlorobenzoic acid (506 mg, 2.12 mmol) in 10 mL of CH 2 Cl 2 containing oxalyl chloride (2.4 mmol). Violent generation of gas was stopped once, the reaction was stirred for 1.5 hours and volatiles were removed using a rotary evaporator. After dissolving crude 5-bromo-2-chlorobenzoyl chloride in 8 mL of CS 2 , the stirred mixture was cooled to 4 ° C. and then anisole (240 mg, 2.12 mmol) followed by AlCl 3 (566 mg, 4.25 mmol) was added. The reaction was warmed to 20 ° C. over 1 h, then stirred for 20 h and quenched with 1N HCl. The suspension was then diluted with 50 mL of H 2 O and stirred until all solid phase dissolved in the solution. The mixture was extracted three times with EtOAc. The combined organic extracts were washed once with 1N HCl, H 2 O, aqueous NaHCO 3 and brine and dried over Na 2 SO 4 . After removal of the volatiles, the residue was eluted with 450 mg of 5-bromo-2-chloro-4'-methoxybenzophenone by chromatography using 15% EtOAc / hexanes on silica gel. [455] B. 5-Bromo-2-chloro-4'-methoxydiphenylmethane [456] 5-bromo-2-chloro- in 3 mL of a mixture of Et 3 SiH (0.45 mL, 2.85 mmol), BF 3 · Et 2 O (0.3 mL, 2.4 mmol) and CH 2 Cl 2 / MeCN (1: 9) A solution of 4'-methoxybenzophenone (450 mg, 1.4 mmol) was stirred at 20 ° C overnight. After quenching with 10% NaOH and diluted with H 2 O, the reaction was extracted three times with EtOAc. The combined organic layers were washed twice with H 2 O, once with brine and dried over Na 2 SO 4 . After removal of the volatiles, the residue was eluted by chromatography using silica gel with 2% EtOAc / hexane as a colorless oil 416 mg of 5-bromo-2-chloro-4'-methoxydiphenylmethane. [457] C. [458] [459] 1.9 M n-BuLi 0.36 in hexane to a -78 ° C stirred solution of 5-Bromo-2-chloro-4'-methoxydiphenylmethane (212 mg, 0.68 mmol) of Part B in 8 mL of dry THF in argon atmosphere. mL was added dropwise. After 30 minutes, the solution was transferred by cannula to a -78 ° C stirred solution of 2,3,4,6-tetra-0-benzyl-β-D-glucolactone (0.39 g, 0.71 mmol) in 5 mL of THF. The solution was stirred at -78 ° C for 2 h and quenched with saturated aqueous NH 4 Cl. After warming to 20 ° C., the reaction was diluted twice with H 2 O and extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, the residue was chromatographed on silica gel with 20% EtOAc / hexanes to give 142 mg of the desired title lactol. [460] D. [461] [462] To the -40 ° C stirred solution of the lactose (142 mg, 0.18 mmol) of Part C in 1.5 mL of MeCN was added iPr 3 SiH (0.041 mL, 0.2 mmol), followed by BF 3 Et 2 O (0.026 mL, 0.2 mmol). It was. After 2 hours at −40 ° C., when TLC indicated the reaction was complete, saturated aqueous NaHCO 3 was added and diluted with H 2 O and CH 2 Cl 2 . The combined organic layers from CH 2 Cl 2 3 extracts were washed with brine, dried over Na 2 SO 4 and concentrated using a rotary evaporator. The residue was chromatographed on silica gel with 25% EtOAc / hexanes as eluent to afford 139 mg of the desired beta C-arylglucoside. [463] E. [464] [465] A solution of Tetra-O-benzyl C-glucoside (136 mg, 0.18 mmol) of Part D in EtSH (1.0 mL) containing BF 3 · Et 2 O (0.46 mL, 3.6 mmol) at 20 ° C. for 4 h. Was stirred. The reaction was diluted with CH 2 Cl 2 and then concentrated using a rotary evaporator. The residue was dissolved in CH 2 Cl 2 , washed with aqueous NH 4 Cl, H 2 O, brine, dried over Na 2 SO 4 and concentrated using a rotary evaporator. The crude product was purified by preparative HPLC using a C 18 reversed phase column and lyophilized to give the desired beta as white lyophilisate. [466] 26 mg of C-glucoside were obtained. [467] HPLC retention time: 3.07 min, purity 95%, detected with YMC S5 C-18 4.6x50 mm column, 2.5 mL / min, 220 nM; Hold for 4 minutes at 100% B after a gradient of 0-100% B for 4 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 . [468] [469] Example 13 [470] [471] A. 5-Bromo-2-methoxy-4'-ethylbenzhydrol [472] To an -78 ° C stirred solution of p-bromoethylbenzene (2.03 g, 11 mmol) in 10 mL of dry THF under argon atmosphere was added 5 mL of 2.5 M n-BuLi (12 mmol) in hexane over 10 minutes. After the temperature was raised to −10 ° C. over 2 hours, the reaction was cooled to −78 ° C. and solid 5-bromo-2-methoxybenzaldehyde (2.15 g, 10 mmol) was added. After stirring at 20 ° C. overnight, the reaction was quenched with saturated aqueous NH 4 Cl, diluted 5 times with H 2 O and extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 1.44 g of 5-bromo-2-methoxy-4'-ethylbenzhydrol was eluted by chromatography on silica gel with 10% EtOAc / hexanes. [473] B. 5-Bromo-2-methoxy-4'-ethyldiphenylmethane [474] 5-Bromo-2-methoxy-4'-ethylbenzhydrol (1.44 g, 4.5 mmol), Et 3 SiH (0.75 mL, 5 mmol) and BF 3 .Et 2 O (0.6 mL) of the crude part A 9 mL of a solution of CH 2 Cl 2 / MeCN (1: 8) containing 6.4 mmol) was stirred at 20 ° C. overnight. After quenching with saturated aqueous NaOH, the mixture was extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 1.28 g of 5-bromo-2-methoxy-4'-ethyldiphenylmethane was eluted by chromatography on silica gel with 2% EtOAc / hexanes. [475] C. [476] [477] 1.8 M n-BuLi in hexane to a -78 ° C stirred solution of 5-Bromo-2-methoxy-4'-ethyldiphenylmethane (0.25 g, 0.82 mmol) of Part B in 7 mL of dry THF under argon atmosphere. 0.5 mL was added dropwise. After 2 hours, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone (0.48 g, 0.9 mmol) in 3 mL of THF was added over 1 minute. The solution was stirred at -78 ° C for 2 h and quenched with saturated aqueous NH 4 Cl. After warming to 20 ° C., the reaction was diluted five times with H 2 O and extracted three times with EtOAc. The combined EtOAc fractions were washed with brine and dried over Na 2 SO 4 . After concentration using a rotary evaporator, 0.67 g of the desired title lactol was obtained as a pale yellow syrup and used in the next step without further purification. [478] D. [479] [480] To the -30 ° C stirred solution of the Lactol (450 mg, 0.59 mmol) of Part C in 10 mL of MeCN was added iPr 3 SiH (0.2 mL, 0.9 mmol), followed by BF 3 Et 2 O (0.1 mL, 0.7 mmol). It was. After 1.5 hours at −40 ° C., after confirming that the reaction was complete by TLC, the reaction was quenched by addition of aqueous NaHCO 3 and then extracted three times with EtOAc. The combined organic layers were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The residue was chromatographed on silica gel with 10% EtOAc / hexanes to give 320 mg of the desired beta C-arylglucoside. [481] E. [482] [483] A solution of tetra-0-benzyl C-glucoside (320 mg, 0.7 mmol) of the above part D in EtOAc (15 mL) containing 10% Pd (OH) 2 / C (30 mg) was subjected to H 2 1 atm. Stir overnight. After confirming by HPLC that the reaction was complete, the catalyst was filtered off and the solvent was removed using a rotary evaporator. The crude product was further purified by preparative HPLC using a C 18 reversed phase column and lyophilized to give 24 mg of the desired beta C-glucoside as a white solid. [484] HPLC retention time: 3.84 min, purity 95%, YMC S5 C-18 4.6x50 mm column, 2.5 mL / min, detection at 220 nM; Hold for 4 minutes at 100% B after a gradient of 0-100% B for 4 minutes. Solvent A: 10% MeOH / H 2 O + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 O + 0.2% H 3 PO 4 . [485] [486] <Example 14> [487] [488] A. N-ethyl-N-4-methoxybenzyl-2,6-dihydroxybenzamide [489] To a stirred solution of N-ethyl-4-methoxybenzyl amine (1.07 g, 6.49 mmol) in DMF (10 mL) was added 2,6-dihydroxybenzoic acid (1.0 g, 6.49 mmol), followed by HOAt (0.97 g, 7.14). mmol) and EDC (1.31 g, 6.81 mmol) were added. After stirring overnight, the reaction was diluted with EtOAc and washed three times with H 2 O. The combined aqueous layers were extracted once with EtOAc. The organic extracts were combined, washed once with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The residue was chromatographed on silica gel using 75% EtOAc / hexanes as eluent. The resulting expected impurity fractions were further purified by chromatography on silica gel. A total of 631 mg of the desired N-ethyl-N-4-methoxybenzyl 2,6-dihydroxybenzamide was obtained. [490] B. [491] [492] The stirred suspension of the amide (630 mg, 2.09 mmol), CdCO 3 (939 mg, 5.44 mmol) of Part A in toluene (30 mL) was refluxed using a Dean Stark trap for 1.5 hours and , 2,3,4,6-tetra-O-acetyl-α-D-glucosofyranosyl bromide (1.12 g, 2.72 mmol) was added. After 15 hours of reflux, the starting material amide did not remain by TLC analysis. [493] The hot suspension was filtered through celite, washed with hot PhMe, followed by three times with hot CHCl 3 . After removing volatiles using a rotary evaporator, the residue was chromatographed on silica gel. A mixture of 0-glucoside was eluted with EtOAc / hexanes (1: 1) to give tetraacetate of the title C-glucoside (172 mg of heavily contaminated title C-glucoside). [494] C. [495] [496] The impurity ester of Part B was stirred for 16 h in EtOH / H 2 0 (6: 1, 1.4 mL) containing KOH (140 mg, 2.5 mmol). The resulting solution was cooled to 4 ° C., acidified to pH 5 and then extracted twice with EtOAc. The combined EtOAc layers were washed with brine, dried over Na 2 S0 4 and concentrated using a rotary evaporator. The desired title C-glucoside (7.8 mg) was eluted by purification with preparative HPLC equipped with a C 18 YMC reversed phase column, gradient of the residue to MeOH / H 2 O (45-90%) for 30 min. [497] HPLC: 99.1%; Shimadzu LC-6A, YMC S3 ODS (6.0 × 150 mm); Flow rate 1.5 mL / min; Detection at 220 nM; 0-100% B gradient elution for 30 minutes (A = 90% H 2 0, 10% MeOH, 0.2% H 3 PO 4 , and B = 90% MeOH, 10% H 2 0, 0.2% H 3 PO 4 ); Retention time = 23.4 min. [498] [499] <Example 15> [500] [501] A. [502] [503] Example 3 β-m-bromophenyl-C-glucoside of part B (100 mg, 0.14 mmol), p-methylphenylboronic acid (59 mg, 0.43 mmol), Na 2 CO 3 (46 mg, 0.43 mmol) And a mixture of Pd (PPh 3 ) 4 (153 mg, 0.13 mmol) in PhMe / EtOH (3: 1) at 80 ° C. for 15 h under argon atmosphere. After removal of the volatiles using a rotary evaporator, the residue was chromatographed using hexanes / EtOAc (10: 1) on silica gel to give the desired title biphenyl C-glucoside (90 mg) as a clear oil. [504] B. [505] [506] Stirring a solution of CH 2 Cl 2 (0.4 mL) of -78 ℃ of tetra-0-benzyl ether (65 mg, 0.09 mmol) of Part A above was added to a 1M BCl 3 in 0.37 mL CH 2 Cl 2 under an argon atmosphere . After 1 hour, the reaction was quenched with 2 mL of MeOH and warmed to 20 ° C. The pH was adjusted to about 7 with aqueous NaHCO 3 and the suspension was extracted twice with CH 2 Cl 2 . The combined organic layers were dried over MgSO 4 and concentrated. The resulting residue was purified by preparative HPLC using a C 18 reversed phase column to give 6.6 mg of the final title product. (Note that the product is partially degraded by the strong acid medium prepared after the MeOH quench of BCl 3 ) [507] HPLC retention time: 6.353 min, purity 100%, zobox C-18 4.6x50 mm, 2.5 mL / min, detection at 220 nM; Hold at 100% B for 5 minutes after a gradient of 0-100% B for 8 minutes. Solvent A: 10% MeOH / H 2 0 + 0.2% H 3 PO 4 . Solvent B: 90% MeOH / H 2 0 + 0.2% H 3 PO 4 . [508] [509] <Examples 16 to 80> [510] The compounds of Examples 16-80 shown in Tables 1 and 2 below were prepared using the methods of Examples 1-15 and Schemes 1-9 above. A, which may be linked at the ortho, meta or para position of the aryl ring bound to the glucoside may be any one of (CH 2 ) n , O, NH or S, while R 1 , R 2 , R 2a , R It will be appreciated that 3 and R 4 may be any substituent as defined above, may be prepared using the methods of Examples 1-15 and Schemes 1-9. [511] [512] [513] [514] [515]
权利要求:
Claims (29) [1" claim-type="Currently amended] A compound having the structure of formula (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug ester thereof. <Formula I> Where R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , alkyl, CF 3 , OCHF 2 , OCF 3 , SR 5i or halogen, or two of R 1 , R 2 and R 2a to which they are attached A cyclized 5 which, together with carbon, forms a 5-, 6- or 7-membered carbocyclic ring or may contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring; Can form a six-, six- or seven-membered heterocycle; R 3 and R 4 are independently hydrogen, OH, OR 5a , Oaryl, OCH 2 aryl, alkyl, cycloalkyl, CF 3 , -OCHF 2 , -OCF 3 , halogen, -CN, -C0 2 R 5b ,- CO 2 H, COR 6b , -CH (OH) R 6c , -CH (OR 5h ) R 6d , -CONR 6 R 6a , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -S0 2 R 5 g , -SO 2 aryl, or a 5 or 6 membered group which may contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring Or a 7-membered heterocycle, or R 3 and R 4 together with the carbon to which they are attached form a 5-, 6- or 7-membered carbocyclic ring or 1 to 4 N, 0, S, SO and (Or) form a cyclized 5-, 6- or 7-membered heterocycle which may contain a SO 2 heteroatom; R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5 g , R 5h and R 5i are independently alkyl; R 6 , R 6a , R 6b , R 6c and R 6d are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a together with the nitrogen to which they are attached 1 to 4 N in the ring To form a cyclized 5-, 6- or 7-membered heterocycle which may contain 0, S, SO and / or SO 2 heteroatoms; A is 0, S, NH or (CH 2 ) n , where n is 0 to 3; Provided that when A is (CH 2 ) n (where n is 0, 1, 2 or 3) or A is 0 and at least one of R 1 , R 2 and R 2a is OH or OR 5, then R 1 , At least one of R 2 and R 2a is CF 3 , OCF 3 or OCHF 2 and / or at least one of R 3 and R 4 is CF 3 , —OCHF 2 —OCF 3 , —CN, —C0 2 R 5b , CH (OR 5h ) R 6d , CH (OH) R 6c , COR 6b , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -SO 2 R 5 g or -SO 2 aryl. [2" claim-type="Currently amended] The compound of claim 1, wherein A is (CH 2 ) n , wherein n is 0, 1, 2 or 3 or A is 0 and at least one of R 1 , R 2 , R 2a , R 3 and R 4 . If one is OH or OR 5 , at least one of R 1 , R 2 and R 2a is CF 3 , OCF 3 or OCHF 2 and / or at least one of R 3 and R 4 is CF 3 , -OCHF 2 -OCF 3 , -CN, -C0 2 R 5b , CH (OR 5h ) R 6d , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -SO 2 R 5 g , -SO 2 aryl or halogen. [3" claim-type="Currently amended] The compound of claim 1 having the structure of formula IA. <Formula IA> [4" claim-type="Currently amended] The compound of claim 1, wherein A is (CH 2 ) n . [5" claim-type="Currently amended] The compound of claim 3, wherein A is CH 2 , O or S. 5. [6" claim-type="Currently amended] The method of claim 1, A is CH 2 , O or S; R 1 , R 2 and R 2a are independently selected from H, lower alkyl, halogen, OR 5 or OCHF 2 , or two of R 1 , R 2 and R 2a are H and the remainder is lower alkyl, halogen, OR 5 or OCHF 2 ; R 3 and R 4 are independently lower alkyl, OR 5a , -OCHF 2 , -SR 5e , OH, CO 2 R 5b , -3,4- (O-CH 2 -0)-, -COR 6b , -CH (OH) R 6c , -CH (OR 5h ) R 6d , CF 3 , , -SOR 5f , -SO 2 R 5 g , aryl, -NHSO 2 aryl, -NHSO 2 R 5d , CO 2 H, thiadizol, tetrazole, OCH 2 aryl, -OCF 3 , Oaryl or H Compound. [7" claim-type="Currently amended] The compound of claim 6, wherein A is CH 2 ; R 1 is hydrogen, halogen or lower alkyl; R 2 and R 2a are each H; R 3 is H; R 4 is lower alkyl, —COR 6b , —CH (OH) R 6c , —CH (OR 5h ) R 6d , R 5a O, —OCHF 2 , —OCF 3 or —SR 5e . [8" claim-type="Currently amended] 8. A compound according to claim 7, wherein A is CH 2 ; R 1 is hydrogen, halogen or lower alkyl; R 4 is lower alkyl, R 5a O, —OCHF 2 or —SR 5e . [9" claim-type="Currently amended] The compound of claim 7, wherein R 4 is 4-C 2 H 5 . [10" claim-type="Currently amended] The compound of claim 3 having the structure of formula: [11" claim-type="Currently amended] The compound of claim 1 having the structure of: Where A is CH 2 and is linked to the meta position relative to the glucoside, R 1 , R 2 and R 2a are each H, R 3 is 4-Me, 4-OH, 3-Me, H, 3-OMe, 4-CO 2 Me, 3,4- (OCH 2 O), 4-CF 3 , 4-NHAc, 4-SO 2 Me, 4-Ph, 4-NHSO 2 Ph-4'-Me, 4-NHSO 2 Me, 4-CO 2 H, 4-thiadiazole, 4-tetrazole, 4-OCH 2 Ph-4'-CN , 4-OCHF 2 , 4-isopropyl, 2-isopropyl, 4-On-propyl, 4-tetrazol-2'-Me, 4-tetrazol-1'-Me, 4-OPh, 4-n- Propyl, 4-n-butyl, 4-SO 2 Et, 4-SO 2 -n-propyl, 4-SO 2 Ph or 4-SOMe. [12" claim-type="Currently amended] The compound of claim 1 having the structure of: [13" claim-type="Currently amended] The compound of claim 1 having the structure of: [14" claim-type="Currently amended] The compound of claim 1 having the structure of: [15" claim-type="Currently amended] A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier thereof. [16" claim-type="Currently amended] An antidiabetic agent, an anti-diabetic agent, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an atherosclerosis agent, and / or a lipid lowering agent other than the sodium dependent glucose transporter (SGLT2) inhibitor compound according to claim 1, and an SGLT2 inhibitor. pharmaceutical formulations comprising a lipid-lowering agent). [17" claim-type="Currently amended] The pharmaceutical combination according to claim 16 comprising said SGLT2 inhibitor compound and an antidiabetic agent. [18" claim-type="Currently amended] The method of claim 17, wherein the antidiabetic agent is a biguanide, sulfonyl urea, glucosidase inhibitor, PPAR γ agonist, PPAR α / γ dual agonist, aP2 inhibitor, DP4 inhibitor, insulin sensitizer, glucagon-like peptide Combination of one, two, three or more of -1 (GLP-1), insulin, meglitinide, PTP1B inhibitor, glycogen phosphorylase inhibitor and / or glucose-6-phosphatase inhibitor. [19" claim-type="Currently amended] 19. The antidiabetic agent according to claim 18, wherein the antidiabetic agent is metformin, glyburide, glymepiride, glypyrid, glyphizide, chlorpropamide, glyclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl. -262570, Isaglitazone, JTT-501, NN-2344, L895645, YM-440, R-119702, AJ9677, Repaglinide, Nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, Combination of one, two, three or more of LY315902 and / or NVP-DPP-728A. [20" claim-type="Currently amended] The combination of claim 17, wherein the SGLT2 inhibitor compound is present in a weight ratio of about 0.01 to about 300: 1 relative to the antidiabetic agent. [21" claim-type="Currently amended] The combination of claim 16, wherein the anti-obesity agent is a beta 3 adrenergic agent, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta compound, and / or an appetite suppressant. [22" claim-type="Currently amended] The combination of claim 21, wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine and / or marginol. [23" claim-type="Currently amended] The combination of claim 16, wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of LDL receptor activity, a lipoxygenase inhibitor, or an ACAT inhibitor. [24" claim-type="Currently amended] The method of claim 23, wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nyvastatin, bisastatin, atavastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate, Combination of Abashimibe, TS-962, MD-700 and / or LY295427. [25" claim-type="Currently amended] The combination of claim 23, wherein the SGLT2 inhibitor is present in a weight ratio of about 0.01 to about 300: 1 relative to the lipid lowering agent. [26" claim-type="Currently amended] The onset or progression of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, insulin, comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need thereof A method of treating or delaying hyperglycemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, syndrome X, diabetes complications, atherosclerosis or hypertension, or increasing high density lipoprotein levels. [27" claim-type="Currently amended] The method of claim 26, wherein the SGLT2 inhibitor compound has the structure of: [28" claim-type="Currently amended] A therapeutically effective amount of a compound of claim 1 alone or in combination with another antidiabetic agent, antidiabetic agent, anti-obesity agent, antihypertensive agent, antiplatelet agent, anti- atherosclerosis agent and / or hyperlipidemia agent in need of treatment A method of treating type II diabetes, comprising. [29" claim-type="Currently amended] Compounds having the structure of the formula: or pharmaceutically acceptable salts, all stereoisomers and prodrug esters thereof: (Wherein R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , lower alkyl, CF 3 , OCHF 2 , OCF 3 , SR 5i or halogen, or two of R 1 , R 2 and R 2a are bonded to A cyclized ring to form a cyclized 5-, 6- or 7-membered carbocyclic ring with carbon or to contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring; Can form a 5-, 6- or 7-membered heterocycle; R 3 and R 4 are independently hydrogen, OH, OR 5a , Oaryl, OCH 2 aryl, lower alkyl, cycloalkyl, CF 3 , -OCHF 2 , -OCF 3 , halogen, -CN, -C0 2 R 5b , -CO 2 H, -CONR 6 R 6a , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -S0 2 R 5 g , -SO 2 aryl, or a ring Are 5-, 6- or 7-membered heterocycles which may contain 1 to 4 N, 0, S, SO and / or SO 2 heteroatoms, or R 3 and R 4 together with the carbon to which they are attached A cyclized 5-membered, 6-membered to form a cyclized 5-, 6- or 7-membered carbocyclic ring or contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring; To form a 7-membered or 7-membered heterocycle; R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5 g and R 5i are independently lower alkyl; R 6 and R 6a are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a together with 1 to 4 N, 0, S, SO and (or ) Forms a cyclized 5-, 6- or 7-membered heterocycle which may contain S0 2 heteroatoms; A is 0, S, NH or (CH 2 ) n where n is 0 to 3; Provided that A is (CH 2 ) n where n is 0, 1, 2 or 3 or A is 0 and at least one of R 1 , R 2 , R 2a , R 3 and R 4 is OH or OR 5 , at least one of R 1 , R 2 and R 2a is CF 3 , OCF 3 or OCHF 2 and / or at least one of R 3 and R 4 is CF 3 , -OCHF 2 -OCF 3 , -CN , -C0 2 R 5b , CH (OR 5h ) R 6d , CH (OH) R 6c , COR 6b , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -SO 2 R 5 g , -SO 2 aryl or halogen); or Compounds having the structure of the formula: or pharmaceutically acceptable salts, all stereoisomers and prodrug esters thereof: (Wherein R 1 , R 2 and R 2a are independently hydrogen, OH, OR 5 , lower alkyl, CF 3 , OCHF 2 , OCF 3 , SR 5i or halogen, or two of R 1 , R 2 and R 2a are bonded to A cyclized ring to form a cyclized 5-, 6- or 7-membered carbocyclic ring with carbon or to contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring; Can form a 5-, 6- or 7-membered heterocycle; R 3 and R 4 are independently hydrogen, OH, OR 5a , Oaryl, OCH 2 aryl, lower alkyl, cycloalkyl, CF 3 , -OCHF 2 , -OCF 3 , halogen, -CN, -C0 2 R 5b , -CO 2 H, -CONR 6 R 6a , -NHCOR 5c , -NHSO 2 R 5d , -NHSO 2 aryl, aryl, -SR 5e , -SOR 5f , -S0 2 R 5 g , -SO 2 aryl, or a ring Are 5-, 6- or 7-membered heterocycles which may contain 1 to 4 N, 0, S, SO and / or SO 2 heteroatoms, or R 3 and R 4 together with the carbon to which they are attached A cyclized 5-membered, 6-membered to form a cyclized 5-, 6- or 7-membered carbocyclic ring or contain 1 to 4 N, 0, S, SO and / or S0 2 heteroatoms in the ring; To form a 7-membered or 7-membered heterocycle; R 5 , R 5a , R 5b , R 5c , R 5d , R 5e , R 5f , R 5 g and R 5i are independently lower alkyl; R 6 and R 6a are independently hydrogen, alkyl, aryl, alkylaryl or cycloalkyl, or R 6 and R 6a together with 1 to 4 N, 0, S, SO and (or ) Forms a cyclized 5-, 6- or 7-membered heterocycle which may contain S0 2 heteroatoms; A is 0, S, NH or (CH 2 ) n, where n is 0 to 3
类似技术:
公开号 | 公开日 | 专利标题 JP5951843B2|2016-07-13|Inhibitors and methods for dipeptidyl peptidase IV having a cyclopropyl-fused pyrrolidine skeleton US8802715B2|2014-08-12|Crystal forms of saxagliptin and processes for preparing same KR100918322B1|2009-09-22|Heterocyclic boronic acid compounds JP3915116B2|2007-05-16|Novel pyrazole derivatives and therapeutic agents for diabetes containing them US6887870B1|2005-05-03|Heterocyclic sodium/proton exchange inhibitors and method DE60122193T2|2007-07-05|Glucopyranosyloxybenzylbenzen derivatives and medical compositions containing these compounds EP1948665B1|2013-02-27|Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists KR100682419B1|2007-02-28|Oxa- and Thiazole Derivatives Useful as Antidiabetic and Antiobesity Agents US7053106B2|2006-05-30|Substituted acid derivatives useful as antidiabetic and antiobesity agents and method RU2254340C2|2005-06-20|Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions comprising these derivatives and intermediate compounds for preparing indicated derivatives CA2476800C|2010-08-17|Crystals of glucopyranosyloxybenzyl benzene derivative JP5475636B2|2014-04-16|Pharmaceutical formulation containing dapagliflozin propylene glycol hydrate CN103145773B|2015-07-22|Crystalline solvates and complexes of | -1, 5-anhydro-L-C- | methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes JP4579681B2|2010-11-10|Substituted heterocycloderivatives and methods useful as antidiabetic and antiobesity agents US7420059B2|2008-09-02|HMG-CoA reductase inhibitors and method US7635699B2|2009-12-22|Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods FI116975B|2006-04-28|Propiophenone derivative and process for its preparation CN101595109B|2012-09-05|7,8-dihydro-1,6-naphthyridin-5|-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods US7659281B2|2010-02-09|HMG-CoA reductase inhibitors EP1658066B1|2009-09-30|Adamantylglycine- based inhibitors of dipeptidyl peptidase iv for the treatment of diabetes JP3794618B2|2006-07-05|Aryl-substituted propanolamine derivative, process for producing the same, medicament containing the compound and use thereof EP1831180B1|2015-07-29|Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods CN101528718B|2011-11-09|Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof CN102066393B|2014-07-02|Novel synthesis of galactoside inhibitors US7507757B2|2009-03-24|Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
同族专利:
公开号 | 公开日 NO20021721D0|2002-04-11| MX237254B|2006-05-26| EG24515A|2009-08-19| IL148806A|2010-06-16| MXPA02003625A|2002-10-23| BR0014722A|2003-02-25| BRPI0014722B1|2019-09-24| DE60020259T2|2006-01-19| IN2007MU00019A|2007-08-03| AU781009B2|2005-04-28| WO2001027128A1|2001-04-19| AT295848T|2005-06-15| CA2388818A1|2001-04-19| CA2388818C|2012-07-03| HU230727B1|2017-12-28| EP1224195A1|2002-07-24| HU229446B1|2013-12-30| CN1284793C|2006-11-15| KR100728085B1|2007-06-14| EP1224195B1|2005-05-18| AU7848300A|2001-04-23| CO5251414A1|2003-02-28| NO332798B1|2013-01-14| HU0300393A2|2003-06-28| US6414126B1|2002-07-02| HU0300393A3|2003-09-29| HK1044541A1|2005-11-11| PT1224195E|2005-07-29| UY26391A1|2001-05-31| JP2003511458A|2003-03-25| PL204358B1|2010-01-29| JP4365554B2|2009-11-18| NZ518029A|2004-08-27| NO20070149L|2002-06-10| TWI254714B|2006-05-11| NO20021721L|2002-06-10| TR200200986T2|2002-07-22| RU2262507C2|2005-10-20| HK1044541B|2005-11-11| DE60020259D1|2005-06-23| PE20011000A1|2001-11-25| RU2002109477A|2004-01-20| CZ20021285A3|2003-02-12| PH12000002657B1|2006-02-21| IL148806D0|2002-09-12| NO323698B1|2007-06-25| PL355018A1|2004-03-22| AR026024A1|2002-12-26| CN1407990A|2003-04-02| ES2240179T3|2005-10-16| CZ304522B6|2014-06-18|
引用文献:
公开号 | 申请日 | 公开日 | 申请人 | 专利标题
法律状态:
1999-10-12|Priority to US15877399P 1999-10-12|Priority to US60/158,773 2000-04-05|Priority to US19461500P 2000-04-05|Priority to US60/194,615 2000-10-02|Application filed by 브리스톨-마이어스스퀴브컴파니 2000-10-02|Priority to PCT/US2000/027187 2002-08-05|Publication of KR20020063876A 2007-06-14|Application granted 2007-06-14|Publication of KR100728085B1 2012-02-01|First worldwide family litigation filed
优先权:
[返回顶部]
申请号 | 申请日 | 专利标题 US15877399P| true| 1999-10-12|1999-10-12| US60/158,773|1999-10-12| US19461500P| true| 2000-04-05|2000-04-05| US60/194,615|2000-04-05| PCT/US2000/027187|WO2001027128A1|1999-10-12|2000-10-02|C-aryl glucoside sglt2 inhibitors| 相关专利
Sulfonates, polymers, resist compositions and patterning process
Washing machine
Washing machine
Device for fixture finishing and tension adjusting of membrane
Structure for Equipping Band in a Plane Cathode Ray Tube
Process for preparation of 7 alpha-carboxyl 9, 11-epoxy steroids and intermediates useful therein an
国家/地区
|